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Chair: Steven P. Schwendeman 
 
 
 Many anticancer drugs, due to their hydrophilicity, have poor drug loading in 
nanoparticles, which has limited efficient drug delivery. Charge-charge interactions may 
be effective for improving loading where charges in nanoparticles attract oppositely 
charged drug molecules. A new strategy, incorporation of charged hydrophobic 
excipients into nanoparticles followed by drug loading via incubation of nanoparticles in 
the presence of drug solution, may effectively increase drug loading. 
 First, hydrophobic alkyl sulfates were tested for improved loading of a model 
hydrophilic drug, doxorubicin hydrochloride (doxHCl). Ion pairing between alkyl 
sulfates and doxHCl yielded hydrophobic complexes based on solubility and partition 
coefficient determinations and indicated favorable incorporation into hydrophobic 
nanoparticle cores. However, encapsulation into nanoparticles failed due to poor complex 




 A more hydrophobic series of borate-based anionic excipients was then studied. 
Solubility studies found ethyl acetate to be a suitable organic solvent for dissolving 
borate-based excipients at high concentrations. One of the excipients, potassium 
tetrakis(4-chlorophenyl) borate (KTpClPB), was the best candidate as it had 
characteristics suitable for nanoparticle incorporation and extraction of doxHCl into a 
hydrophobic phase. A new incubation loading strategy was utilized for drug uptake into 
nanoparticles. Optimization of this process found maximizing free acid number of 
polymers, amount of KTpClPB used, and drug:nanoparticle ratio increased drug loading. 
Increasing incubation temperature both increased polymer strand rearrangements and 
promoted drug uptake. PEGylation of nanoparticles, or adding PEG-PLA polymers into 
the formulation, reduced nanoparticle aggregation to promote drug uptake. 
 Using the optimized incubation loading procedure, a second model drug, 
vinblastine sulfate, also achieved high drug loading, demonstrating that this procedure 
may be more broadly applicable. Plasma drug uptake using optimized nanoparticles and 
incubation loading led to successful extraction of doxHCl at high plasma drug 
concentrations, suggesting potential application of these nanoparticles as drug detoxifiers.  
 Comparison of incubation loading with traditional drug loading procedures (O/W 
or W/O/W emulsions), found traditional drug loading produced half the loading relative 
to incubation loading due to limited drug extraction into organic phase of O/W emulsions 
and limited inner aqueous phase volume of W/O/W emulsions. In vitro drug release 
profiles were similar for all nanoparticles, and the presence of KTpClPB, despite charge 
attractions, failed to slow drug release. Further drug loading optimization found that 
changing incubation times did not change drug loading, while reducing polymer 
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concentration of nanoparticles improved drug loading due to smaller size and increased 
surface area-to-volume ratio. 
 Hence, the novel nanoparticles and encapsulation approach developed here may 



















































 Drug delivery has evolved over the last several decades to become more 
sophisticated and efficacious for treating diseases of interest. Since the early days, when 
simple dosage forms such as pills and topical creams were the norm, more sophisticated 
systems, such as injections, infusions, and implants, have been developed for treating the 
multitude of diseases with different sites and mechanisms of action. 
 A few notable achievements in drug delivery include 1) special coatings for drug 
tablets or pills, which have resulted in extended-release formulations where the active 




) and site-specific coating that protect 
the active ingredient from degradation at a specific location (such as the acidic 
environment of the stomach); 2) development of drug patches (Nicoderm
®
) with 
extended release of active ingredient that can penetrate through the skin to reach the 
bloodstream (Fig. 1.1); and 3) development of nanoparticulate carriers to entrap and 
deliver anticancer drugs to disease sites (an example is Doxil
®
, a liposomal carrier of 
doxorubicin hydrochloride). 
1.1.2 Drug delivery devices: goals 
 
 Even with the present accomplishments in drug delivery, more breakthroughs are 
still needed to further improve the efficacy of existing drugs. To achieve these 
breakthroughs, it is important to understand the goals for drug delivery. For the purposes 
of improving drug delivery, the goals are all similar and include: 1) protecting drugs from 
degradation during formulation or dosage preparation and after administration into the 
 2 
 
body; 2) controllable release period to achieve desirable body residence time or increased 
dosing intervals; 3) enhanced targeting of drug molecules to disease sites; 4) reducing 
overall side effects; and 5) creating safer formulations that can work broadly to improve 
efficacy of many classes of drugs.  
1.1.3 Extended release delivery systems 
1.1.3.1 Microspheres 
 
 One of the goals scientists have targeted is controlled drug release. Many drugs, 
such as chemotherapeutics, require multiple injections or infusions, while others require 
taking many pills multiple times each day to maintain therapeutic level in patients. 
Because this can lead to patient discomfort, extended release drug delivery devices are 
desirable. An early device for this was microspheres, or envelopes containing drug-
dissolved solution (Poznansky and Juliano 1984) and now defined as polymeric spheres 
between 1-999 micrometers that can be formulated using solvent evaporation or various 
polymerization methods (Kreuter 1996; Freiberg and Zhu 2004). These particles can 
entrap or encapsulate drug molecules to protect the integrity of drugs under physiological 
conditions, reduce potential side effects through localized release, as well as release drug 
slowly over an extended period of time (weeks to months) depending on formulation 
parameters. 
Early studies used albumin, polyvinylpyrrolidone, and polyacrylamide to 
formulate microspheres (Fig. 1.2), but problems included poor release kinetics, 
inflammatory reactions, or restrictions in the types of drugs that can be delivered (Kramer 
1974). A breakthrough in this field came when biodegradable and biocompatible 
polymers were used to formulate an implant that reduced immune responses and achieved 
sustained drug release over 100 days (Langer and Folkman 1976), drastically reducing 
the number of administrations needed while maintaining therapeutic concentrations in the 
body. In the 30+ years since this advancement, numerous classes of drugs, including 
proteins (antibody) and peptides (Langer 1996; Duncan, Jess et al. 2005; Li and 
Schwendeman 2005; Wang, Tabata et al. 2006), small molecules (Lamprecht, Yamamoto 
et al. 2003; Abdekhodaie and Wu 2006), and genetic material (Yun, Goetz et al. 2004; 
 3 
 
Jang and Shea 2006) have been encapsulated into or adsorbed onto these biodegradable 
microspheres for improved efficacy or release. 
1.1.3.2 Millicylinders 
 
In addition to microspheres, another local extended release formulation is the 
millicylinder, which are cylinders in the millimeter range in length and micrometers in 
diameter with drugs dispersed throughout a polymer matrix. However, they are less 
extensively studied relative to microspheres because  of the larger needle used or even 
surgery used to administer this dosage form, even though drug loading and release can be 





, where levonorgestrel, the active ingredient, is dispersed throughout the 
matrix of silicone rods (Fig. 1.3). 
Even though microspheres and millicylinders are effective for extended and 
controlled drug delivery and preservation of drug integrity, they lack target specificity 
and their relatively large size only allows for local administration and drug release 
(Kohane 2006). Because of these inherent disadvantages, another class of controlled drug 
delivery vehicle with targeting and systemic administration properties, nanoparticles, has 
been studied extensively in recent years. 
1.2 Nanoparticle drug delivery systems 
1.2.1 Introduction/background 
 
As the name suggests, nanoparticles are solid particles ranging from 10 nm to 
1000 nm in size (Kreuter 1996). They have many of the characteristics and advantages of 
microspheres and they can be made from different materials depending on the type of 
nanoparticles and different types of drugs, including proteins, peptides, small molecules, 
and genetic material, that are loaded into the particles.  
Even though most people know nanoparticles are effective for drug delivery, 
many do not realize that there are different types of nanoparticle formulations that vary 
depending on formulation procedure, materials used, type of drug encapsulated, drug 
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distribution in the particle, morphology and size of the particles. Thus, a thorough 
understanding of prevalent formulations is required to successfully prepare nanoparticle 
delivery vehicles. Below, brief overviews of popular nanoparticle formulations are 
presented. 
1.2.2 Nanoparticle carriers 
1.2.2.1 Liposomes 
 
One of the earliest nano-scale formulations investigated were liposomes (Fig. 
1.4A). Their discovery dates to the 1960s, when it was found that hydrated dry lipid films 
can form spherical vesicles resembling cellular organelles with lipid bilayers (Bangham 
1993). After more than 40 years of extensive study, liposomes are now broadly defined as 
spherical lipid bilayers from 50-1000 nm in diameter with the lipid bilayer enclosing an 
inner aqueous phase (Banerjee 2001; Lian and Ho 2001). The lipid bilayer can be 
constructed from different phospholipids along with different amounts of cholesterol to 
increase particle stability. Different phospholipids impart different properties (e.g., 
charges) to liposomes. For example, phosphatidylserine and phosphatidylglycerol result 
in negative surface charge which can reduce particle aggregation and improve stability 
while dioleoyl phosphatidylethanolamine result in positive surface change valuable for 
loading and delivering DNA (Farhood, Serbina et al. 1995). In addition to constituent 
material, liposomes are also distinguished into unilamellar or multilamellar vesicles. As 
the names suggest, unilamellar vesicles have single lipid bilayer surrounding an aqueous 
core while multilamellar vesicles have multiple lipid bilayers surrounding the aqueous 
core. Because they have aqueous core surrounded by lipid bilayers, hydrophilic drugs 
may be encapsulated in the aqueous core while hydrophobic drugs can be entrapped in 
the lipid bilayer. 
An important factor for the efficacy of liposomes, and perhaps nanoparticles in 
general, is particle size. Extensive investigations showed that liposome uptake by the 
reticuloendothelial system (RES), a system that clears particles from the bloodstream and 
thus reduces particle/drug circulation time, increases with particle size (Banerjee 2001; 
Lian and Ho 2001). In addition to size, another aspect of liposomes that will be discussed 
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in detail later is the targeting ability of these particles. Different molecules, such as 
antibodies, may be coated or conjugated onto the surface of liposomes to promote 
localization to a particular type of cell in the body that overexpress receptors for these 
molecules. 
Extensive research for the last several decades have led to numerous successful 
marketed drugs using liposome technology (Dutta 2007). 
1.2.2.2 Micelles 
 
Micelles are another type of nanoparticles with enormous potential for the 
delivery of hydrophobic drugs. The basic unit of a micelle is a block copolymer with 
amphiphilic character where one segment is hydrophobic while the other is hydrophilic 
(Fig. 1.4B). In an aqueous environment, copolymers assemble to form polymeric micelles 
with a hydrophobic core and a hydrophilic shell. Copolymer association occurs when 
their solution concentration reach a threshold value, known as the critical micelle 
concentration (CMC). Unlike micelles formed from surfactants such as sodium dodecyl 
sulfate (SDS), polymeric micelles have a much lower CMC, improving their stability in 
body. Other advantages of micelles include relatively uniform small size, which normally 
varies between 10-100 nm; ease of preparation and drug loading; and innate stealth effect, 
the ability to repel body protein adsorption onto particle surface and removal by 
macrophages, due to a outer shell of hydrophilic polymer (Kataoka, Harada et al. 2001; 
Croy and Kwon 2006). However, one of the important limitations of a micelle is the type 
of drugs it can deliver. Because of the hydrophobic core of this carrier and passive 
nanoparticle formulation procedure, hydrophobic drugs are most suitable for loading 
although some researchers have also loaded genetic material (Katayose and Kataoka 
1998) and enzymes (Harada and Kataoka 1998) into micelles formulated using ionic 
copolymers. 
Even though no micelle-based drugs are currently marketed, micelle-based 
formulations of doxorubicin HCl (NK911) and taxol (NK105) have entered clinical trials 





Dendrimers are another nanoparticle formulation extensively researched in recent 
years. This carrier was first illustrated in 1979 by Vogtle and pioneering work by 
Tomalia (Tomalia, Baker et al. 1985) and Newkome (Newkome, Yao et al. 1985) in the 
mid-1980s helped to establish this field of study. Dendrimers are essentially repeatedly 
branching units (dendrons) radiating from a central core with individual/identical 
branching units made from monomer units linked to each other through covalent bonds 
(Fig. 1.4C). The number of branching points tallied moving outward from the core to the 
periphery of the dendrimer defines its generation (G-1, G-2, G-3…). The most commonly 
used dendrimer scaffold is polyamidoamine (PAMAM), built from a core of ethylene 
diamine (EDA), and tested for applications in MRI and drug delivery (Lee, MacKay et al. 
2005; Svenson and Tomalia 2005; Yang and Kao 2006).  
There are currently two methods to produce dendrimers, divergent and convergent 
methods. The divergent method was first introduced by Tomalia and is where monomer 
units extend peripherally from the core in a radial fashion while the convergent method, 
pioneered by Frechet, proceeds from the surface to form identical branches or dendrons 
and then attachment of these to a multifunctional core to form the dendrimer (Svenson 
and Tomalia 2005). 
Dendrimers have various characteristics advantageous for drug delivery. These 
include: 1) construction from almost any type of chemistry (polyamidoamines, 
polyamines, polyamides, polyesters, DNA, etc.) that is usefully for tailoring their 
solubility and degradability; 2) potential for controlled surface functionality or 
multivalency that allows multiple drug conjugation for drug loading and multiple antigen 
attachment for active drug targeting; and 3) and well-defined structure with very low 
polydispersity (uniform size) which can improve drug targeting and reduce therapeutic 
variability (Lee, MacKay et al. 2005). 
Despite being around for a little more than 20 years, dendrimer-based technology 
has become very pervasive with commercial products such as Starburst
™
 by Dendritech, 
VivaGel
™
 by Starpharma as a topical microbicide to prevent STD transmission, 
Superfect
®
 by Qiagen for gene transfection, Alert Ticket
™
 by US Army Research 
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Laboratory for anthrax detection and Stratus
®
 CS for cardiac marker diagnostics (Yang 
and Kao 2006).  
1.2.2.4 Solid lipid nanoparticles (SLN) 
 
As the name suggests, solid lipid nanoparticles are made from solid lipids (lipids 
solid at room and body temperature) stabilized by surfactants with drug dissolved or 
dispersed in the particle matrix (Fig. 1.4D). This field was discovered in the 1960s when 
the first parenteral fat emulsion (Intralipid
®
) was used for nutrition delivery. However, 
previous formulations in this field used liquid oils with small size, making controlled 
drug release difficult (Mehnert and Mader 2001; Wissing, Kayser et al. 2004; Wong, 
Bendayan et al. 2007); thus, the concept of solid lipid usage was conceived. 
The basic ingredients of SLN include solid lipids, including triglycerides, partial 
glycerides, fatty acids, steroids, and waxes, and emulsifiers and water. There are four 
general methods of SLN preparation. The first is high shear 
homogenization/ultrasonication where lipid pellets are reduced in size. The second is 
high pressure homogenization at hot or cold temperature, where the lipid suspension or 
emulsion is reduced in size using a high pressure homogenizer. The third is solvent 
emulsification/evaporation where like micelles, the lipids and drug are dissolved in 
water-immiscible organic solvent and emulsified in an aqueous phase. Lastly, one of the 
more recent methods is microemulsion-based SLN preparation where the components 
chosen and their ratios help to control particle formation and size (Mehnert and Mader 
2001; Wissing, Kayser et al. 2004). 
Drug can be loaded into the core or shell of solid lipid nanoparticles, and in many 
cases, may be dispersed in the lipid matrix. Because the lipid matrix is made from 
physiological lipids, SLN can also reduce toxicity although certain formulations require 
high concentrations of stabilizing surfactant/emulsifiers that may be toxic in itself. 
Nowadays, innovations in this area has led to hybrid polymer/lipid SLN that improve 
particle stability and drug loading and release (Wong, Bendayan et al. 2007). 




Other nanoparticulate drug carriers include albumin nanoparticles, which can be 
prepared by emulsion formation, desolvation, or coacervation methods. However, a 
surfactant-free pH-coacervation method has become the standard with the introduction of 
the first albumin nanoparticle-based drug, Abraxane
®
 (Langer, Balthasar et al. 2003). 
Another potential carrier are magnetic nanoparticles although to this day, they are used 
more as a diagnostic tool due to poor drug loading. 
1.2.2.6 Polymeric nanoparticles 
 
With the above nanoparticulate drug carriers in mind, we now focus on the most 
relevant and important nanoparticle formulation for this project, polymeric nanoparticles. 
As its name suggests, these nanoparticles can be thought of as solid particles composed 
of intertwining polymer strands. Although recently, distinctions between polymeric 
nanoparticles and other polymer-based nanoparticles such as dendrimers and micelles 
have been blurred. 
Polymeric nanoparticles have been made from many types of polymers ranging 
from basic polymers such as poly(lactide-co-glycolide) (PLGA), poly(lactic acid) (PLA), 
chitosan, poly(alkylcyanoacrylate) (PACA) such as polybutylcyanoacrylate, poly(ε-
caprolactone) (PCL), etc, to more complex diblock and triblock polymers such as 
poly(ethylene glycol)-poly(lactide acid) (PEG-PLA) (Soppimath, Aminabhavi et al. 2001; 
Galindo-Rodriguez, Allemann et al. 2004; Astete and Sabliov 2006). 
PLGA (Fig. 1.5) is a polymer commonly used to formulate nanoparticles; it is 
synthesized through ring-opening polymerization of two monomer components, lactic 
acid and glycolic acid, linked through hydrolysable ester bonds. Due to its 
biodegradability and biocompatibility, PLGA is very often used in FDA-approved 
devices such as Lupron Depot
®
, which is prescribed for treatment of advanced prostate 
cancer (Sinha and Trehan 2005). 
1.2.2.6.1 Formulation procedures 
 
There are numerous reported procedures for formulating polymeric nanoparticles, 
and almost all of them fall under several categories. These methods for nanoparticle 
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formulation include: 1) emulsion/solvent evaporation; 2) nanoprecipitation; 3) monomer 
polymerization; 4) salting-out; and 5) spray-drying method (Govender, Stolnik et al. 
1999).  
In the emulsion/solvent evaporation method, polymer is dissolved in organic 
solvents such as dichloromethane and this is emulsified into an aqueous solution with a 
suitable surfactant for particle stability. Extraction of the oil phase into aqueous phase 
leads to hardening of the nanoparticles. This is the basic oil-in-water (O/W) emulsion 
(Fig. 1.6). Other variations include water-in-oil-in-water (W/O/W) where a small volume 
of aqueous solution is first emulsified into the oil phase to form a W/O emulsion, then 
this is emulsified into a larger volume aqueous solution to form the W/O/W particles; 
solid-in-oil-in-water (S/O/W) (Kumar, Ramakrishna et al. 2006) emulsion, where solid 
drug is suspended/emulsified into polymer-containing oil phase, then the S/O primary 
emulsion is emulsified into an outer aqueous phase to form the S/O/W nanoparticles; and 
less extensively used O/O emulsion, where two immiscible organic solvents, one 
containing the polymer and drug, are emulsified to form nanoparticles. In the above 
procedures, drug loading can be achieved through dissolution (in the inner aqueous or oil 
phase) or dispersion (as a solid in the oil phase) during nanoparticle formulation 
(Soppimath, Aminabhavi et al. 2001; Astete and Sabliov 2006). 
In the nanoprecipitation method, nanoparticle hardening occurs spontaneously 
when a water-miscible organic solvent containing dissolved polymer and drug is slowly 
mixed with and displaced into a surfactant-containing aqueous phase (Govender, Stolnik 
et al. 1999). This technique is easy and reproducible; however, because only a small 
number of drugs are soluble in water-miscible organic solvents, this limits the 
applications of this procedure.  
The salting-out method, researched sparingly, was patented by Doelker and 
colleagues (Bindschaedler, Gurny et al. 1988). In this procedure, a polymer-dissolved 
organic phase, which should be water-miscible, is emulsified in an aqueous phase under 
strong stress. The aqueous phase contains an emulsifier and a large amount of 
undissolved salt to prevent organic phase displacement. Then addition of pure water to 
this emulsion with careful mild stirring will gradually reduce the ionic strength and 
induce organic solvent displacement and particle formation (Astete and Sabliov 2006).  
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The monomer polymerization method, as the name suggests, uses monomeric 
units such as alkyl cyanoacrylates and mixes them mechanically in an acidic aqueous 
media, in the presence of surfactants at room temperature, to form nanoparticles 
containing polymers such as poly(alkylcyanoacrylate) (PACA). The drug is dissolved in 
the medium before or after polymerization for loading (Soppimath, Aminabhavi et al. 
2001).  
Lastly, in the spray-drying technique, dried nanoparticles are created in a one-step 
process. A feed solution containing polymer and drug is first added into a spray-drying 
instrument and then atomized into a spray. As the spray droplets contact air, they are 
dried and the solid nanoparticles sediment for collection (Raffin, Jornada et al. 2006; 
Tewa-Tagne, Briancon et al. 2006). The size of these particles is based on orifice size of 
the nozzle and atomizing pressure. Advantages of this technique include a one-step 
formulation process and ease of scale-up while disadvantages include variable yields, 
potentially low drug loading and dispersed size (Raffin, Jornada et al. 2006).  
With all the different techniques listed above, it is no surprise that the polymeric 
nanoparticle approach is one of the most versatile for drug loading. While at this stage, it 
is difficult to proclaim any one of the techniques as better than others, the 
emulsion/solvent evaporation method has been extensively studied due to its simple 
procedure and broader drug applicability relative to the other methods. For this reason, 
this nanoparticle formulation strategy will be the focus of this project. 
1.2.2.6.2 Distinguishing features of polymeric nanoparticles 
 
Despite similarities to other nanoparticle carriers, polymer nanoparticles have 
many important advantages. For example, as solid polymers, their stability is excellent 
relative to nanoparticles such as micelles, which spontaneously form above the critical 
micelle concentration (CMC) of constituent copolymers and could collapse below this 
concentration, and liposomes, which are made of fragile lipid bilayers. In addition, 
polymeric nanoparticles can be tailor-made to promote simple entrapment of different 
types of drugs (hydrophilic or hydrophobic, small molecule or proteins/peptides), 
whereas carriers such as micelles are most suitable for loading hydrophobic small 
molecule drugs and carriers such as dendrimers, although suitable for loading 
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hydrophobic or hydrophilic drugs, require complicated chemical conjugation for drug 
loading (Yokoyama 2005). Also, compared to dendrimers, which are made through 
chemical synthesis, polymeric nanoparticles could be formulated more easily through 
emulsion-based methods with relatively less stress. Liposomes, although used for several 
marketed drugs, are relatively unstable compared to polymeric nanoparticles as 
mentioned above (Wissing, Kayser et al. 2004), and are not the best candidates for 
achieving long-term (weeks to months) controlled release due to their fragile outer shell 
that could collapse in two days or less. Solid lipid nanoparticles, although stable and 
suitable for long-term release, present challenges for drug loading due to their harsh 
formulation conditions.  
1.2.2.6.3 Drug loading methods 
 
 Drug incorporation into polymeric nanoparticles can be categorized into 
entrapment during nanoparticle formulation, drug conjugation to polymer strands before 
or after nanoparticle formulation, and drug absorption in preformed nanoparticles. 
 Drug entrapment is by far the most commonly used strategy. Common examples 
of this involve water-in-oil-in-water (W/O/W) and oil-in-water (O/W) emulsion 
nanoparticles. With this traditional strategy, drug molecules are either dissolved or 
suspended in the inner aqueous or oil phase of emulsion-based nanoparticles; as 
nanoparticles form, drugs are entrapped in the polymer matrix or may even partition into 
the polymer matrix in the case of hydrophobic drugs to promote drug loading.  
 Conjugation drug loading is less common. This involves either chemical 
conjugation of drug and polymer and then use of these conjugates to form nanoparticles 
or chemical conjugation of drugs to pre-formulated blank nanoparticles. This method has 
not been widely adopted mainly because of the small number of reactive sites available 
on nanoparticles for drug loading as well as finding suitable conjugation reactions that 
will not degrade any components. 
 Absorption loading, or in certain cases, adsorption, is also less commonly used 
(Fig. 1.7). Here, pre-formulated nanoparticles are suspended in an aqueous drug solution 
(in rare cases, certain organic solvents may also be used for drug dissolution as long as 
nanoparticle integrity is not compromised), and incubation conditions may be 
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tailored/altered to produce desirable results. This strategy has been applied extensively to 
proteins/peptides, which lose efficacy under stressful nanoparticle formulation conditions. 
With the potential to alter incubation drug loading conditions, depending on the type of 
drug and nanoparticle used, this strategy may prove to be the most useful and will be 
explored further in this project. 
1.2.2.6.4 Release mechanisms/stages 
 
A very important consideration for polymeric nanoparticles is drug release rate. In 
a perfect world, drug release from polymeric nanoparticles, or any nanoparticle 
formulation for that matter, would be zero-order with continuous drug release over days, 
weeks, or months depending on the drug and indication of interest. Unfortunately, due to 
the small diameter of nanoparticles, surface area-to-volume ratio is very large and can 
lead to burst release of the majority of encapsulated drug over the first few hours and 
little release afterwards.  
Through extensive studies over the years on microspheres and nanoparticles, 
scientists have elucidated the mechanism by which drug molecules are released from 
polymeric matrices of particles. During the initial stage, drugs loosely bound to or 
embedded on particle surfaces are released upon contact with bulk release media. Then, 
drugs in the surface layer of nanoparticles may be released from pores near the surface 
(hydrophilic drugs) or partition through the polymer phase to the bulk aqueous phase 
(hydrophobic drugs). Next, drugs in the core of nanoparticle matrix diffuse out, with 
hydrophilic drugs released through aqueous channels while hydrophobic drugs diffuse 
out through the hydrophobic polymeric matrix. Also during this stage, the polymer may 
become increasingly swollen due to water absorption, further facilitating drug diffusion 
through the polymer matrix. For larger particles such as microspheres, there is also a final 
stage when the polymer matrix erodes and bulk particle degradation occurs, leading to 
release of any remaining drug. For nanoparticles, however, their small size usually cause 
the majority of drug to be released long before this stage can take effect (Jalil and Nixon 
1990; Soppimath, Aminabhavi et al. 2001).  
In order to achieve zero-order release, the only proven ways scientists have 
slowed drug release from nanoparticles is either through the use of hydrolysable linkers 
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conjugating drug to the polymer (hydrolysis-limiting) or converting drugs to hydrophobic 
forms with poor water solubility (solubility-limiting) (Budhian, Siegel et al. 2008). In an 
example of hydrolysis-limiting release, Yoo et al. (Yoo, Oh et al. 1999) achieved one 
month, nearly zero-order release of doxorubicin from PLGA nanoparticles. However, 
formulation of these particles was complex as doxorubicin was first chemically 
conjugated to PLGA before formulation and drug loading was less than desirable (around 
3.5% w/w). Coincidentally, doxorubicin hydrochloride is also a hydrophilic drug which 
can be converted to a hydrophobic form with the addition of materials such as 
triethylamine during nanoparticle formulation, and this improves drug loading and 
release. The above information illustrates that unless an additional layer of attraction, 
such as chemical linkage or phase attraction between drug molecules and the polymer 
matrix can be implemented, slow controlled release of the drug is very difficult to 
achieve. 
1.2.2.6.5 Research obstacles 
 
Having looked at various nanoparticle formulations as well as important 
properties of polymeric nanoparticles, we now focus our attention on the 
emulsion/solvent-evaporation formulations. Relative to other formulation strategies, 
emulsion/solvent-evaporation has been extensively studied due to broader applicability to 
numerous classes of drugs, the ability to tailor formulations according to different needs, 
and the availability of a large arsenal of polymers, each with their unique properties; 
however, there are still numerous obstacles for this strategy.  
Some obstacles for emulsion/solvent-evaporation nanoparticles include large 
dispersity of particle sizes, which may lead to potentially different biodistribution and 
release rates; potential degradation of certain drugs due to stressful formulation procedure; 
burst release of drug, as mentioned above, where a large percentage of encapsulated drug 
is released from particles within a few hours of administration and may cause toxicity; 
poor targeting of drug-loaded particles to disease sites, leading to reduced efficacy and 
side effects; and relatively low drug loading for hydrophilic drugs, which could require 
increases in the total amount of drug and nanoparticles administered for each dose and 
increase of administration time.  
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As mentioned before, higher nanoparticle drug loading is desirable due to direct 
benefits such as reduced dosage amount (weight) and administration time and more 
extended release interval as well as indirect benefits such as reduced side effects and 
increased administration interval. However, for many categories of drugs, such as 
proteins, peptides, vaccines, genetic material, and small molecules, high drug loading into 
emulsion-based nanoparticles has been difficult to achieve. Drug loss could occur in 
different stages of the formulation process such as sonication-induced emulsification 
(where drugs may not be encapsulated or degraded) and nanoparticle hardening (where 
hydrophobic drugs escape out with organic solvents or hydrophilic drugs in the surface 
layer diffuse out into the hardening media). With this issue in mind, a superior alternative 
could be the absorption drug loading method mentioned earlier. Because loading 
conditions can be tailored depending on the type of drug and nanoparticle used and 
different variables may be optimized to produce the best results, this could provide a 
powerful tool for drug loading. Normally, absorption loading of drug into polymeric 
nanoparticles occurs via a passive concentration gradient driving drugs into the particles; 
however, the presence of an active or charge-based uptake mechanism, in addition to 
passive concentration gradient, could significantly improve drug loading. The uptake 
mechanism we will explore is ion complexation or ion-exchange. 
1.3 Ion complexation/pairing 
1.3.1 Background 
 
Ion complexation strategies have been used to stabilize proteins/peptides in 
solution and involved pairing of oppositely charged small molecules (hydrophobic in 
many cases) to proteins/peptides to form new entities. Recently, because hydrophilic 
small molecule drugs have poor compatibility with the hydrophobic core of polymeric 
nanoparticles, leading to poor drug loading, ion complexation has been used to provide 
additional attraction between the nanoparticle and drug to improve loading (Eroglu, Kas 
et al. 2001; Ubrich, Bouillot et al. 2004; Wong, Bendayan et al. 2004; Wong, Rauth et al. 
2006). An example of this is where the ionizable group of a drug, such as the positive 
amine group of doxorubicin, is electrostatically attracted to negative charges incorporated 
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into the nanoparticle, such as acid groups on polymer strands. Various studies have 
demonstrated the effectiveness of ion complexation strategy in nanoparticles for 
improving drug loading, release profile, and changes in biodistribution, using either 
specially-tailored polymers/copolymers (Cavalli, Gasco et al. 2002; Wong, Bendayan et 
al. 2004; Wong, Rauth et al. 2006; Chavanpatil, Khdair et al. 2007; Tian, Bromberg et al. 
2007) or polymer building-blocks such as dextran sulfate (Janes, Fresneau et al. 2001) or 
alginate (Cafaggi, Russo et al. 2007) as counterions. 
1.3.2 Specific applications for proteins 
 
 Despite the effectiveness of ion complexation for nanoparticle drug delivery, the 
majority of existing research has been applied to protein/peptide loading via drug 
absorption or adsorption, where blank nanoparticles are incubated with a concentrated 
protein or peptide solution and drug is taken up into the particles. In these cases, special 
anionic polymers or copolymers that have been synthesized to promote protein/peptide 
loading include sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) to 
incorporated tetanus toxoid (Jung, Breitenbach et al. 2000), poly(ε-caprolactone)-
poly(ethylene glycol)-poly(ε-caprolactone) to enhance human basic fibroblast growth 
factor incorporation (Gou, Huang et al. 2007) and using poly(styrene-co-4-styrene-
sulfonate) to enhance lysozyme loading (Cai, Bakowsky et al. 2008). These examples 
have demonstrated significantly improved drug loading while minimizing drug 
degradation during the loading process. 
1.3.3 Lipophilic anion use in nanoparticles as ion complexing agents 
 
 Despite the ingenuity that has made ion complexation an effective tool for drug 
delivery, integration of this with polymeric nanoparticles have focused on specially 
synthesized polymers or copolymers which are complex in design and fabrication. An 
interesting alternative or addition to the use of anionic polymers would be incorporation 
of lipophilic anions that could be obtained cheaply and easily. The lipophilicity of these 
molecules could promote their incorporation into hydrophobic cores of polymeric 
nanoparticles while their anionic charges could enhance drug loading. Small molecule 
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lipophilic anions that could be studied for this purpose include sulfate-based compounds, 
such as sodium dodecyl sulfate, and borate-based compounds, such as sodium tetraphenyl 
borate. These compounds have either hydrophobic carbon chains or aromatic rings linked 
to either anionic sulfates or borates which would be ideal for entrapment in the 
hydrophobic core of nanoparticles while the anionic charge would be beneficial for 
improving uptake of cationic drugs, especially hydrophilic small molecules. 
1.4 Applicable cationic drugs 
 
There are numerous classes of hydrophilic, positively charged drugs which could 
benefit from ion complexation. Examples include anesthetics such as bupivacaine 
hydrochloride; tricyclic antidepressants such as amytriptyline and desipramine; 
antibiotics such as gentamycin sulfate and capreomycin sulfate; and hypertension drugs 
such as amiloride. 
One of the most important classes which will be the focus of this study is 
chemotherapeutic drugs, which includes doxorubicin hydrochloride (doxHCl) and 
vinblastine sulfate (VS), two excellent candidates (model drugs) for incorporation into 
ion-complexing/pairing nanoparticles (Fig. 1.8). An important indicator of suitability of 
the drug is its pKa value; doxHCl has a pKa of around 8.2, meaning that at physiological 
pH of 7.4, more than 80% of doxHCl molecules have a net positive charge; vinblastine 
sulfate (VS) has a pKa of around 7.4, meaning that around 50% of VS molecules have a 
net positive charge at physiological pH. These pKa values demonstrate both drugs have 
the ability to interact with counter-anions to form hydrophobic ion pairs.  
In addition to having desired molecular charges at physiological pH, these 
hydrophilic drugs have aqueous solubility of greater than 10 mg/mL and both drugs have 
been commercially available for the last several decades and are effective against a range 
of cancer cells. Despite their effectiveness, delivery of these drugs using nanoparticles 
have further improved efficacy through passive drug targeting while reducing side effects, 
but drug loading in polymeric nanoparticles have been limited by their hydrophilicity.  
In addition to potential charge-charge interactions between positively charged 
drug molecules and negative charges of the anions to provide an active drug uptake into 
nanoparticles, the fused rings of doxHCl and VS may also have hydrophobic interactions 
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(pi-pi stacking) with aromatic rings of the lipophilic borates used, such as sodium 
tetraphenylborate.  
1.5 Alternative applications of ion complexing/pairing polymeric nanoparticles 
 
 Drug delivery is only one of the applications for lipophilic anion-incorporated 
polymeric nanoparticles, but based on the potential for active drug and opposite charge 
uptake; other applications may also be possible for these versatile devices. Two of the 
potential applications include treatment for drug detoxification and water purification.  
1.5.1 Drug detoxification 
 
Drug overdose has been one of the major healthcare problems around the world 
and can result from causes such as therapeutic mishaps by physicians or nurses, illegal 
drug uses, or suicide attempts. Despite mounting morbidity and financial burdens, the 
majority of drug-induced toxicities still lack appropriate treatment (Litovitz 1998). 
1.5.1.1 Current detoxification strategies 
 
There are five primary detoxification methods widely used today. The most often 
cited is hemodialysis and hemofiltration, where semi-permeable membranes separate 
counter-current dialysate and extracorporeal blood to remove drugs. However, important 
shortcomings of this include suitability only for a small number of hydrophilic drugs with 
low molecular weight, low volume of distribution, and slow onset of action due to long 
procedure duration. A second method, similar to hemodialysis, is plasmapheresis, where 
extracorporeal exchange of plasma with treated donor plasma or saline takes place. 
Similar to hemodialysis, this strategy involves additional complexities related to 
exchange of plasma itself. The third method is use of drug-specific antibodies through 
either direct injection or extracorporeal immunoadsorption. However, due to limited 
binding sites, large quantities of antibodies need to be administered in order to be 
effective. To date, only Digibind®, used for treating digoxin toxicity, has been 
commercially available. The fourth method is the traditional use of drug-specific 
antidotes, although only two, atropine and naloxone, have been manufactured and 
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available to treat muscarinic-cholinergic and narcotic receptor antagonists. Although 
rarely used, the last method involves direct infusion of enzymes to degrade drugs into 
inactive metabolites, such as the use of butyrylcholinesterase to degrade cocaine (Dennis, 
Martin et al. 2001; Kaminski and Rosengart 2005). 
Although these are the primary methods, other cheaper but effective methods 
include induced vomiting and stomach washes. 
1.5.1.2 Nanoparticle detoxification strategies 
 
Due to limitations of the existing detoxification methods, a few nanoparticle 
systems have been explored as potential detoxifying agents. Early research in this area 
include the use of custom-designed microemulsions to extract lipophilic drugs into 
lipophilic inner cores (Morey, Varshney et al. 2004; Varshney, Morey et al. 2004), 
magnetic nanoparticles that can capture toxins through surface-conjugated receptors 
(Kaminski and Rosengart 2005; Mertz, Kaminski et al. 2005), and larger derivatized 
oligochitosan molecules that achieve rapid amitriptyline adsorption through pi-pi 
complexation (Lee and Baney 2004; Lee, Flint et al. 2005). Despite successful drug 
uptake, shortcomings of these systems include relative instability of microemulsions in a 
physiological system and complex synthesis and characterization for derivatized 
magnetic particles and chitosan as well as uncertainty regarding how well these systems 
work physiologically. 
A new biodegradable polymeric nanoparticle system could overcome these 
shortcomings. By taking advantage of and selecting best-available commercially 
available polymers, such as  poly(lactic acid) (PLA), poly(ε-caprolactone) (PCL), and 
FDA-approved poly(lactide-co-glycolide) (PLGA) (Astete and Sabliov 2006) as well as 
incorporation of a lipophilic anion that improves drug partitioning into the nanoparticle, 
we can synthesize an effective, stable and simple system for detoxification. 
1.5.2 Hard water treatment 
 
Another potential application of ion-complexing nanoparticles may be water 
treatment. Water hardness, due to the presence of heavy metals magnesium and calcium, 
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pose significant problems for cleaning (domestic applications such as laundry and 
bathing and industrial scale applications), causing buildup in pipes which restrict water 
flow over time, and causing buildups in thermal generators (water heating element) 
which increases the cost of heating water over time (Robison 2008). For humans, water 
hardness may increase the risk of acute myocardial infarction (Yang, Chang et al. 2006; 
Kousa, Havulinna et al. 2008) and irritant contact dermatitis (Warren, Ertel et al. 1996). 
Because of these challenges, research to reduce heavy metal content have been extensive 
and numerous scientist have explored ion-exchange mechanisms for metal removal. 
Examples include cross-linked poly(styrenesulfonamide) with iminoacetic acid (Bicak, 
Senkal et al. 1998) and use of mixture of calcium hydroxide, iron sulfate, lime and 
chlorine to precipitate and sediment heavy metals such as calcium (Sale, Darr et al. 1988). 
 Lipophilic anion-incorporated polymeric nanoparticles in this project may be 
applicable for this process. Presence of lipophilic anions inside nanoparticles and anionic 
charges of PLGA polymers provide a natural ion-exchange mechanism for cationic 
molecules such as heavy metals. Potential aggregation of regular (unPEGylated) 
nanoparticles after surface charge neutralization (due to drug adsorption/binding) also 
provides a built-in mechanism of metal ion removal. In addition, PLGA is biodegradable 
and biocompatible, while selection of lipophilic anion selection should be more carefully 
considered to limit the inherent toxicity associated with this strategy. 
1.6 Specific aims 
 
With all of the above information in mind, there are several objectives that I 
would like to accomplish for this project: 
1) Test the ion pairing ability of a group of alkyl sulfates with a model drug, 
doxorubicin hydrochloride, and determine the solubility of resulting complexes in various 
organic solvents and lastly, examine how well they incorporate into polymeric 
nanoparticles. 
2) Test the ion-pairing ability of a group of borate-based compounds by 
determining their solubility in various organic solvents and ability to extract (ion-pair 
with) doxHCl into an organic phase.  
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3)  Examine incorporation and loading of borate-based lipophilic anions and 
model drugs, doxorubicin hydrochloride and vinblastine sulfate, into polymeric 
nanoparticles, with drug loading achieved using an optimized incubation adbsorption 
method; and test drug uptake under simulated physiological environment. 
4) Compare drug loading (by weight) and release properties, for ion-pairing 
nanoparticles, with drug loaded using either absorption drug loading strategy or 











































































































Figure 1. 2. Representative albumin (A) and polyvinylpyrrolidone (B) microspheres as 





































Figure 1. 3. Norplant
®
















































































































Aqueous Phase:  
water with emusifier 
probe sonicate for 20 sec to 
form O/W emulsion 
Magnetically stir 3-5 hrs 
end product: O/W nanoparticles 
Oil Phase: 2 mL organic solvent 
with polymer and drug 
wash with stir cell 
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Ion Complexation of DoxHCl With Anionic Sulfates and Potential Encapsulation of 




 The purpose of this study was to synthesize hydrophobic complexes of 
doxorubicin hydrochloride (doxHCl) with a series of alkyl sulfates via ionic interactions 
to enhance drug encapsulation into hydrophobic polymeric core of nanoparticles. 
Doxorubicin/alkyl sulfate complexes were prepared through different mixing methods 
and characteristics such as aqueous solubility, partitioning between methylene chloride 
and phosphate-buffered saline (PBS) phases, and cell cytotoxicity relative to doxHCl 
were analyzed. Attempts were made to encapsulate these novel drug complexes into 
polymeric nanoparticles using either solid-in-oil-in-water (S/O/W) or modified water-in-
oil-in-water (W/O/W) methods. Results showed that hydrophobic drug complexes had 
reduced aqueous solubility and increased methylene chloride/PBS partition coefficient 
relative to doxHCl and cell cytotoxicity against K562 leukemia cells were similar for 
drug complexes relative to doxHCl based on EC50 measurements. However, subsequent 
attempts to encapsulate drug complexes into polymeric nanoparticles using S/O/W or 
modified W/O/W emulsions failed as the complexes did not dissolve in organic solvents 
commonly used for nanoparticle preparation and the amphiphilic nature of alkyl sulfates 
actually may have promoted drug loss from nanoparticles. Based on these results, more 
hydrophobic alkyl sulfates or new classes of lipophilic anions need to be utilized for ion 
compexation or ion pairing with doxHCl to promote nanoparticle encapsulation. 
2.2 Introduction 
 
Doxorubicin hydrochloride (doxHCl) is a widely used anticancer 
chemotherapeutic belonging to a family of anticancer drugs known as anthracyclines. 
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This drug is made up of fused rings linked to a sugar moiety with an attached amine 
group with a pKa of 8.2 (Fig. 2.1). Since FDA approval in the 1970s, this drug has been 
successfully used to treat a range of cancers including various leukemias, breast cancer, 
ovarian cancer, various lymphomas, etc. (Information; Langer and Folkman 1976; 
Beijnen 1991). Despite its potent activity, doxHCl has a number of disadvantages 
including short plasma circulation half-life, long elimination half-life, and nonspecific 
cell-cytotoxicity. These shortcomings can lead to dose-limiting side effects including 
cardiomyopathy and myelosuppression (Abraham, Waterhouse et al. 2005; Kang, Cheon 
et al. 2006).  
One way to overcome these problems is to encapsulate doxHCl in drug carriers; 
ones that have been experimentally tested include polymer micelles (Kataoka, 
Matsumoto et al. 2000; Lee, Na et al. 2005), polymeric nanoparticles (Yoo, Oh et al. 
1999; Soma, Dubernet et al. 2000; Yoo, Lee et al. 2000), liposomes (Medina 2004; 
Abraham, Waterhouse et al. 2005), microspheres (Defail 2006; Missirlis, Kawamura et al. 
2006), and hydrogels (Kang, Cheon et al. 2006). Use of depot formulations such as 
microspheres and hydrogels can reduce toxic side effects while providing extended drug 
release that may last up to months. Use of nanoparticulate carriers such as polymeric 
micelles, polymeric nanoparticles and liposomes to deliver doxHCl can confer additional 
advantages such as prolonged circulation half-life and increased accumulation in tumors 
due to EPR (enhanced permeation and retention) effect, where the leaky vasculature and 
poor lymphatic drainage around tumors improve drug retention. 
Polymeric nanoparticles have gained considerable attention due to their ease of 
production, stability, optimal size distribution, increased hydrophobic drug loading and 
controlled/extended drug delivery potential through the use of different polymer(s) 
(Jeong, Cheon et al. 1998; Kataoka, Matsumoto et al. 2000; Yokoyama 2005). DoxHCl 
delivery to tumors could also benefit from the aforementioned attributes, however, due to 
its hydrophilicity, previous studies of doxHCl loading into nanoparticles have shown 
problems such as low encapsulation efficiency and loading into nanoparticles and burst 
release within a few hours after administration leading to significant drug loss and 
potential toxicity. To improve doxHCl loading into and release from polymeric 
nanoparticles, scientists have utilized strategies such as chemical conjugation of 
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doxorubicin to hydrophobic polymers (Yoo, Oh et al. 1999; Yoo, Lee et al. 2000) and 
chemical conversion of doxHCl into its free base (hydrophobic) form through a chemical 
reaction with triethylamine (TEA) (Kataoka, Matsumoto et al. 2000; Gao, Lee et al. 2005; 
Missirlis, Kawamura et al. 2006). 
In this study, a simple process known as hydrophobic ion pairing (HIP), where a 
drug of interest is electrostatically paired with oppositely charged ionic molecule, will be 
used to modify doxorubicin hydrochloride into a new hydrophobic complex in order to 
improve drug loading into and release from polymeric nanoparticles. Here, alkyl sulfates 
such as sodium dodecyl sulfate are complexed with doxHCl; these sulfates have a 
negative sulfate group for pairing with cationic protonated amine group of doxHCl while 
a hydrophobic carbon chain may confer hydrophobicity to the complexes synthesized. 
Properties of the new complexes, such as solubility, partition coefficient, NMR-deduced 
structure and cell cytotoxicity will be compared to doxorubicin hydrochloride. Lastly, 
these complexes will be formulated into nanoparticles and loading and release 
determination. This strategy will be simpler than the aforementioned strategies for 
improving drug loading and release and hydrophobic drug complexes may prove to be 
more potent than the original doxHCl against cancer cells.  
2.3 Materials and Methods 
2.3.1 Materials 
 
 Sodium octyl sulfate (95% purity), sodium dodecyl sulfate (>98% purity), sodium 
tetradecyl sulfate (95% purity), and sodium octadecyl sulfate (93% purity), were 
purchased from Sigma-Aldrich. Doxorubicin hydrochloride (doxHCl) (>99% purity, 
lyophilized powder) was purchased from Hisun Pharmaceuticals (China). Poly(D,L-
lactide-co-glycolide), 50/50, with inherent viscosity of 0.34 dL/g and MWw of 38 kDa 
(resomer 503H) was purchased from Boehringer Ingelheim, and inherent viscosity of >1 
dL/g (high IV, end-capped) was purchased from Alkermes. Poly(vinyl alcohol) (PVA) of 
MWw of 25 kDa (88% hydrolyzed) was purchased from Polysciences Inc. Deuterated 
methanol (>99% purity) was purchased from Cambridge Isotope Laboratories. All other 
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chemicals and solvents were of analytical grade or higher and purchased from 
commercial suppliers. 
 K562 cells were a generous gift from Dr. Gustavo Rosania (University of 
Michigan). RPMI 1640 with and without L-glutamine and pencillin/streptomycin were 
purchased from Gibco Inc. Fetal serum albumin, heat-inactivated, and Vybrant
®
 MTT 
cell proliferation assay kit were purchased from Invitrogen
®
. Costar 96 well round 
bottom cell culture plates, sterile, was purchased from Fisher Scientific. All other 
materials used for cell assays were sterile grade. 
2.3.2 Doxorubicin complex synthesis 
 
2.3.2.1 Sodium octyl sulfate/doxHCl (doxSOS): 1.1:1 molar ratio of SOS and doxHCl 
were dissolved in 2 mL of 5 mM sodium citrate buffer, pH 4. 2 mL of methylene chloride 
was added into the buffered solution followed by vortex mixing. The mixture was shaken 
for 1 hour on a shaker plate (Ika KS130) at 200 shakes/min followed by centrifugation at 
5,000 RPM for 10 minutes. Aqueous phase was collected and spun down at 13,200 RPM 
for 6 minutes to collect the drug complex precipitate. The precipitate was washed twice 
with deionized water (DIW) and lyophilized.  
 
2.3.2.2 Sodium dodecyl sulfate/doxHCl (doxSDS): 0.95:1 molar ratio of SDS and 
doxHCl were each dissolved in 2 mL of DIW. The SDS solution was slowly titrated into 
the doxHCl solution and red precipitate formed immediately. The precipitate was 
collected by centrifugation at 13,200 RPM for 6 minutes and washed twice with DIW 
followed by lyophilization. 
 
2.3.2.3 Sodium tetradecyl sulfate/doxHCl (doxSTS): 0.95:1 molar ratio of STS and 
doxHCl was used. STS was dissolved in 0.1 mL of methanol and doxHCl was dissolved 
in 5 mL of DIW. STS solution was slowly titrated into the doxHCl solution and red 
precipitate formed immediately. The precipitate was collected by centrifugation at 13,200 




2.3.2.4 Sodium octadecyl sulfate/doxHCl (doxSODS): 0.95:1 molar ratio of SODS and 
doxHCl was used. SODS was suspended in 0.1 mL of methanol (suspension with white 
powder) and homogenized by sonication in a sonicating waterbath. DoxHCl was 
dissolved in 6 mL of DIW. SODS suspension was added into the doxHCl solution and 
red precipitate formed immediately. The precipitate was collected by centrifugation at 
13,200 RPM for 6 minutes and washed twice with DIW followed by lyophilization. 
2.3.3 NMR analysis of complexes 
 
DoxHCl and the four drug complexes synthesized were weighed out and 
dissolved in 0.75 mL of methanol-D
4
. The five samples were analyzed using Bruker 
Avance DRX 500. 
2.3.4 HPLC analysis of doxHCl concentration 
 
A Waters HPLC system (Waters, Milford, MA) was used for chromatographic 
separation of doxHCl. It consisted of a 1525 Binary HPLC pump, 717 plus autosampler, 
and 474 scanning fluorescence detector. Waters Breeze
®
 chromatography software was 
used to acquire and process data. A Waters Nova-Pak
®
 C18 column (3.9 x 150 mm I.D.) 
(Waters, Milford, MA) was used with a filtered and degassed ACN : 20 mM, pH 3 
potassium phosphate : TFA (30:70:0.1, v/v/v) mobile phase. Chromatography was 
performed at a flow rate of 1 ml/min and fluorescence detection was set at λexcitation of 480 
nm and λemission of 590 nm at room temperature. 
DoxHCl in the samples were identified by comparing retention time with 
corresponding standards injected separately. 
2.3.5 Drug complex solubility determination 
 
Excess amounts of doxHCl or doxorubicin/sulfate complexes were incubated in 
either phosphated-buffered saline (PBS) or deionized water (DIW) at 37
o
C with shaking 
(200 shakes/min) for 12 hours. Samples were centrifuged at 13,200 RPM for 5 min after 




2.3.6 Partition coefficient measurements 
 
The partition coefficients of doxorubicin/sulfate complexes were determined in 
methylene chloride/phosphate-buffered saline (PBS) mixture at 37
o
C. 
Doxorubicin/sulfate complexes were weighed and dissolved in methylene chloride at a 
concentration of 5 µg/ml. Equal volume of PBS was added to each drug complex solution 
followed by vortex mixing and shaking (200 shakes/min) for 24 hour at 37
o
C to reach 
equilibrium. DoxHCl concentration in PBS, after partitioning, was determined by HPLC 









=/   
2.3.7 In vitro experiments 
2.3.7.1 Cell culture 
 
K562 cells were maintained in tissue culture medium (RPMI 1640 supplemented 
with 10% FBS and 1% penicillin/streptomycin at 37
o
C with 5% CO2). Experiments were 
done with cells in logarithmic growth phase (0.2-1 x 10
6
 cells/mL) 
2.3.7.2 Cell viability experiment 
 
Cytotoxicity of doxHCl and various doxorubicin/sulfate complexes were 
determined using the MTT cell proliferation assay. Briefly, drug solutions at various 
concentrations (0, 0.01, 0.1, 0.25, 0.5, 1, 10, and 100 µg/ml), each containing 200,000 
cells/mL, were made by spiking concentrated drug solutions in methanol into RPMI 
solutions containing 200,000 cells/ml to reach the desired drug concentration. Samples 
were plated at 100 µL/well (20 K cells/well; n = 5) and incubated 48 hours at 37
o
C and 
5% CO2, before starting MTT cytotoxicity assay to determine cell viability. Standard 
curve of various cell concentrations (25,000, 50,000, 100,000, 200,000, and 400,000 
cell/mL) were made for the 48 hour incubation samples and methanol was added to cell 
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solutions at each concentration to ensure same volume ratio of methanol/RPMI relative to 
drug solutions. Results were expressed in terms of EC50 (µg/mL or µM of doxHCl or 
doxorubicin complex) as determined from dose-response curves and defined as the 
concentration of drug complex that produced a 50% reduction in cell viability compared 
to doxHCl. Sigmoidal dose-response curves were fit to the data using SigmaPlot (Systat 
Software Inc.) and used to compute EC50 for each experiment. 
2.3.8 Nanoparticle formulation procedure 
2.3.8.1 Solid-in-oil-in-water (S/O/W) emulsion formulation 
 
Drug complex precipitates were encapsulated into nanoparticles via S/O/W 
emulsion/solvent evaporation procedure. Different amounts of solid drug were weighed 
and suspended in 2 mL methylene chloride (containing 80 mg dissolved polymer) and 
sonicated (60 seconds) on ice using a probe sonicator (Sonics VibraCell) at 100% power. 
The S/O suspension was further emulsified in 4 mL 3% PVA solution by sonication (60 
seconds) on ice using a probe sonicator (Sonics VibraCell) at 100% power. The S/O/W 
emulsion was diluted into 80 mL of 1% PVA solution under rapid magnetic stirring for 4-
5 hours. Nanoparticle suspensions were collected and dialyzed (Spectra/Por 7, MWCO: 
50,000) to remove unencapsulated drug. 
2.3.8.2 Modified water-in-oil-in-water (W/O/W) formulation 
 
Drug-loaded nanoparticles were formulated using a water-in-oil-in-water (W/O/W) 
emulsion/solvent evaporation procedure. DoxHCl was dissolved in 0.3 ml deionized 
water (DIW) at predetermined concentration and emulsified, in a mixture of 1.9 ml 
methylene chloride with 80 mg dissolved polymer and 0.1 ml methanol with 1 mg SOS, 
by sonication (60 seconds) on ice using a probe sonicator (Sonics VibraCell) at 100% 
power. The primary emulsion (W/O) was further emulsified in 4 mL 3% PVA solution by 
sonication (30 seconds) on ice using a probe sonicator (Sonics VibraCell) at 100% power. 
The W/O/W emulsion was diluted into 80 mL 1% PVA solution under rapid magnetic 
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stirring for 4-5 hours. Nanoparticle suspensions were collected and dialyzed (Spectra/Por 
7, MWCO: 50,000) to remove PVA and unencapsulated drug. 
2.3.9 Drug loading determination 
 
Briefly, drug-loaded nanoparticles were lyophilized and weighed into 2 mL 
polypropylene tubes. 0.1 mL methylene chloride was added to nanoparticles, followed by 
shaking for 10 minutes, then addition of 1.5 mL methanol and shaking for over 12 hours. 
These suspensions were spun down at 13,200 RPM for 8 min. Supernatant containing 
dissolved drug was diluted as appropriate using methanol. Drug concentration was 
analyzed using UV doxHCl concentration determination. 
For UV analysis, a Beckman DU650 spectrophotometer was used. Samples or 
standards containing doxHCl were analyzed using a quartz spectrophotometer cell 
(Starna Cells Inc.) at a scanning rate of 1200/min and scanning range of 400-750 nm. 
Absorbance wavelength was set at 480 nm and all samples had baseline reading set at 
750 nm.  
2.3.10 Nanoparticle physical characterization 
2.3.10.1 Particle size/zeta potential determination 
 
Nanoparticle suspensions were diluted to 0.5 mg/mL and transferred into fold 
capillary cells for both zeta potential and particle size determination. Samples were 
analyzed using a Malvern ZetaSizer Nano ZS (Malvern Instruments). 
2.3.10.2 SEM morphological analysis 
 
Nanoparticle suspensions were diluted to 50 µg/mL and dried overnight on 
viewing stubs. Morphology was observed by scanning electron microscopy (Philips 
XL30 Field Emission Gun Scanning Electron Microscopy). 




2.4.1 Doxorubicin complex synthesis 
 
 Many attempts have been made to increase doxorubicin hydrochloride (doxHCl) 
loading into nanoparticles. However, because of its hydrophilicity (>10 mg/ml solubility 
in deionized water), doxHCl loss during formulation and low drug loading/encapsulation 
efficiency were common. To improve doxHCl loading, a potentially effective strategy 
was formation of hydrophobic drug complexes through pairing with lipophilic anions and 
encapsulation of these complexes in nanoparticles. Here, we have tested a series of 
anionic sulfates (Table 2.1) for this strategy. The sulfates had increasing hydrophobicity 
based on theoretical logP values and structure; they were amphiphilic with a hydrophobic 
carbon chain and hydrophilic charged sulfate group. Formation of ion complexes between 
sulfates and doxHCl (Fig. 2.1) could neutralize charged portions of both molecules to 
form a hydrophobic ion pair. 
 Based on complex preparation conditions, ion pairing was the dominant 
interaction between sulfate and doxHCl molecules. This was shown when molar ratios of 
1.1:1, 0.95:1, and 0.95:1 between SDS:doxHCl, STS:doxHCl, and SODS:doxHCl, 
respectively, when mixed in water, formed red complex precipitates and left no visible 
trace of dissolved drug in solution (dissolved doxHCl in water gave a red solution while 
very little or no drug gave a colorless solution). Of the 4 complexes tested, doxSOS 
complex was the least stable (highest aqueous solubility) and hardest to form in large 
quantities while formation of other complexes occurred readily (within seconds of mixing) 
and completely (almost all the dissolved drug had form precipitates with sulfates). This 
was reasonable considering sodium octyl sulfate was the most water-soluble of the four 
sulfates and the short alkyl chain (8 carbons) was not enough to impart the desired levels 
of hydrophobicity. 
2.4.2 Drug complex characterization 
2.4.2.1 NMR analysis 
 
 DoxHCl and its hydrophobic sulfate complexes were dissolved in deuterated 
methanol and analyzed. Despite subtle differences, the NMR spectrum of doxHCl (Fig. 
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2.2) obtained here was similar to previously reported spectrum (Xu, Yang et al. 2005). 
Overlay of the different spectra (Fig. 2.2) showed characteristic peaks associated with 
doxHCl (bottom-most spectrum) and sulfate detergents. Even though characteristic peaks 
of anionic sulfates and doxHCl were observed, there was no peak shift for any doxHCl 
peaks upon complexation with sulfates, which was surprising. 
 Normally, changes in the polarity of hydrogen atoms, caused by events such as 
ion complexation or chemical conjugation, would lead to a shift of the corresponding 
NMR hydrogen peak. Here, even though ion complexation occurred between 
protonatable amine group of doxorubicin and anionic sulfates, there was no peak shift for 
the amine hydrogens of doxorubicin. A potential explanation has to do with methanol 
solvent used for NMR analysis. Since methanol molecules were polar with numerous 
hydroxyl groups, they could cause dissociation of the drug complexes dissolved in it and 
form cages where its hydroxyl groups surround and stabilize the lone charges. 
 Even though empirical evidence demonstrated the formation of hydrophobic 
drug/sulfate complexes, NMR spectra did not directly prove this observation. 
2.4.2.2 Solubility of doxorubicin sulfate complexes 
 
 Solubility of doxorubicin sulfate complexes was compared to that for doxHCl 
(Table 2.2) to ensure the complexes were more hydrophobic. Drug complexes and 
doxHCl were dissolved in either deionized water (DIW) or phosphate-buffered saline 
(PBS), with salt composition and concentrations that mimicked physiological fluids.   
In PBS, doxSOS solubility was about 30% of doxHCl solubility while doxSDS 
and doxSODS had about 3% of doxHCl solubility. Surprisingly, doxSTS, not doxSODS, 
had the lowest PBS solubility at about 1.5% of doxHCl solubility, or 66.7 times lower 
aqueous solubility. In DIW, differences in solubility were even more pronounced. Using 
a reported doxHCl solubility value of greater than 17.24 mM in deionized water, doxSOS 
solubility was 7.5% that of doxHCl solubility, doxSDS solubility was 1.7% that of 
doxHCl solubility, while doxSTS and doxSODS had the lowest solubility at only 0.6% of 
doxHCl solubility. Overall, solubility trends in both PBS and DIW were not surprising as 
doxSOS complexes were the hardest to synthesize under aqueous conditions while other 
complexes formed readily. DoxSTS and doxSODS were expected to have the lowest 
 49 
 
aqueous solubility due to longer alkyl chain lengths (14 and 18 carbons, respectively), 
although it was uncertain why doxSTS, not doxSODS, had the lowest solubility in PBS; 
however, because PBS solubilities of doxSTS and doxSODS were very low to begin with, 
a solubility difference of 1.5% was not significant and could simply be due to 
experimental error. 
Solubility of the complexes could take two forms, they could either dissolve as a 
whole complex in either DIW or PBS, which was minimal due to its hydrophobicity, or 
the complexes may dissociate in the presence of counterions in PBS and each component 
would on its own. With this in mind, in the presence of PBS, doxHCl and doxSOS 
solubilities were 5-10 times lower than corresponding solubilities in DIW (no salt present) 
while doxSDS, doxSTS, and doxSODS showed slightly higher solubilities in PBS than in 
DIW. Higher DIW solubility for doxHCl, relative to that in PBS, matched previously 
known information which suggested they may crash out of solutions at high salt 
concentrations (PBS). Because doxSOS was the most hydrophilic drug complex with 
properties most similar to doxHCl, its dissolution in DIW was also expected to be greater 
than in PBS, where the complexes had a lower solubility and dissociation of the complex 
was limited by solubility of doxorubicin itself. For the other complexes, DoxSDS, 
doxSTS, and doxSODS, which had much lower DIW solubilities relative to that in PBS, 
the situation was actually reversed as the complexes had very low solubilities in both 
DIW and PBS due to their hydrophobicity and the ability of the complexes to dissociate 
in PBS actually led to higher solubilities. 
In all, these results suggested doxSDS, doxSTS, and doxSODS had significantly 
improved hydrophobicity over doxHCl, unlike doxSOS. 
2.4.2.3 Partition coefficient measurements 
 
 Another important property of drug complexes was their partitioning between 
aqueous and organic phases. For this study, PBS was chosen as the aqueous phase to 
mimic drug release into physiological compartments, while methylene chloride, a solvent 
commonly used to formulate nanoparticles and encapsulate drugs, was chosen as the 
organic phase. The four doxorubicin sulfate complexes were dissolved in methylene 
chloride and equilibrated with equal volume of PBS to determine drug concentration and 
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partition coefficient. DoxHCl, with negligible solubility in methylene chloride and 
drastically higher PBS solubility, was not studied. 
 Results (Table 2.3) showed that doxSOS, with the highest aqueous solubility, had 
the lowest methylene chloride/PBS partition coefficient while doxSODS had the highest 
partition coefficient (more drug partitioning into methylene chloride phase). A surprising 
result was that doxSTS had lower partition coefficient relative to doxSDS, which should 
be less hydrophobic, and that doxSTS had partition coefficient of less than 1, indicating a 
higher drug concentration in the aqueous phase. This result was unexpected and may be 
due to experimental errors although it was also likely that actual properties of doxSTS 
may deviate from ones predicted based on their structure. Overall, though, the trend was 
as expected with doxSOS having much lower partitioning coefficients than the other 
three complexes. 
 Despite partition coefficients of >1, which indicated higher partitioning into 
methylene chloride phase and the potential for improved drug encapsulation and loading, 
a major problem encountered here was the low solubilities of the different hydrophobic 
complexes in methylene chloride (low µg/ml range, data not shown). This was a major 
limitation for traditional drug encapsulation strategies which required drug dissolution in 
organic solvents at high concentrations for significant drug loading. 
2.4.3 In vitro cytotoxicity 
 
 To compare the cytotoxicity of doxorubicin complexes on cell viability relative to 
doxHCl, different amounts of doxHCl/doxorubicin complexes were administered to K562 
lymphoma cells and then incubated in a drug-free medium for 48 hours. Cell viability 
after 48 hours was determined using MTT assay and compared to untreated controls. 
After 48 hours, sigmoidal dose-response curves were obtained (Fig. 2.3) for the different 
drugs and EC50 values for K562 cells were obtained (Table 2.4) based on these sigmoidal 
dose-response curves.  
 EC50 could be considered as the drug concentration where half of the initially 
incubated cells were killed after 48 hrs of incubation. On a molar basis, the values for the 
complexes were similar (Table 2.4) although they were slightly higher than that for 
doxHCl, which indicated the complexes had slightly lower efficacy relative to doxHCl 
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although it was not statistically significant. This result was reasonable considering 
doxHCl and doxorubicin complexes were administered to K562 cells at equivalent 
weight amounts, which meant there were less doxorubicin molecules administered in the 
form of hydrophobic complexes as the theoretical molecular weight of the complexes 
increased. Since doxorubicin molecules were the primary cytotoxic agents and the 
complexes required dissociation before doxorubicin can be released, it makes sense that 
the complexes have slightly lower cytotoxicity.  
2.4.4 Solid-in-oil-in-water nanoparticle formulation 
 
 In this study, the ultimate goal was to load doxorubicin sulfate complexes into 
hydrophobic core of polymeric nanoparticles at high concentrations. However, initial 
studies found traditional emulsion/solvent evaporation strategies (O/W or W/O/W) were 
not useful because the drug complexes had low solubilities in methylene chloride, 
chloroform, and ethyl acetate (data not shown), organic solvents commonly used for 
nanoparticle formulation. An alternative formulation strategy utilized was solid-in-oil-in-
water (S/O/W) technique (Bilati, Allemann et al. 2005). Using this strategy, large 
amounts of drug complex precipitates may be suspended in methylene chloride, and after 
intense sonication, their size may be reduced enough for encapsulation into polymeric 
nanoparticles (Fig. 2.4).  
Initial observations of S/O/W nanoparticle emulsions containing doxSDS, 
doxSTS, or doxSODS showed relatively clear red suspensions (not shown) without large 
particles or aggregates. However, after sitting overnight, a thin layer of precipitates 
sedimented in the nanoparticle suspension, which does not occur normally with pure 
nanoparticle suspensions and indicated presence of micrometer (or larger) sized particles. 
Even though initial particle sizing data (not shown) showed a unimodal size distribution 
between 150-200 nm in diameter, SEM images of nanoparticle suspensions (Fig. 2.5) 
showed nanoparticles intermixed with large amounts of micrometer sized strands. This 
was the first time strands like these had been observed. Various attempts were made to 
separate the strands from nanoparticles using differential centrifugation (spinning down 




An initial hypothesis for the identity of these strands focused on drug complex 
precipitates. Because the complexes were sonicated in methylene chloride before 
encapsulation, their size may not have been reduced enough and ended up in the 
micrometer instead of nanometer size range. To test this hypothesis, blank nanoparticles 
(without drug complex addition) were formulated using the same S/O/W formulation 
procedure and SEM image (Fig. 2.6A) showed good nanoparticles without any strands. 
Another study, where only doxSODS precipitate was sonicated in blank methylene 
chloride, and then immediately viewed under SEM, showed drug complex strands in the 
micrometer size range (Fig. 2.6B). These results confirmed the hypothesis that drug 
complex precipitates hindered successful nanoparticle formulation and without a 
sonication device that produces significantly higher sonication power, an alternative 
formulation strategy was required. 
2.4.5 Modified W/O/W nanoparticle formulation 
 
 Knowing that doxorubicin sulfate complexes could not reach nanometer size 
range via sonication with the device on hand and they had low solubility in a range of 
organic solvents, a possible alternative was to first dissolve doxHCl and sulfate 
molecules in different phases and form drug complex precipitates during nanoparticle 
formation. To facilitate this, a modified W/O/W nanoparticle formulation strategy could 
be employed (Fig. 2.4) with doxHCl dissolved in the inner aqueous phase and sulfates 
dissolved in the organic phase. Unfortunately, none of the four sulfates studied dissolve 
well in methylene chloride, chloroform, or ethyl acetate, solvents commonly used for 
nanoparticle formulation. To resolve this problem, a possible alternative solution was to 
dissolve the sulfates, at high concentrations, in another organic solvent miscible with 
methylene chloride and mix that with methylene chloride for nanoparticle formulation. 
The organic solvents tested for this were methanol, acetone, and acetonitrile. 
 Initial studies with STS and SODS had demonstrated poor solubilities in a number 
of organic solvents (not shown), so attention was focused on SOS and SDS. Results 
showed that between SDS and SOS and the three organic solvents tested, only SOS was 
soluble in methanol at a high concentration of >10 mg/ml (Table 2.5), so this 
combination was chosen to formulate W/O/W nanoparticles with doxHCl in the inner 
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aqueous phase and a combination of 1.9 ml methylene chloride with dissolved polymer 
and 0.1 ml methanol with dissolved SOS as the organic phase. 
 Nanoparticle emulsion was successfully formulated as clear red nanoparticle 
suspensions and no sedimentation was observed overnight. SEM images (Fig. 2.7) 
confirmed the observations as ~200 nm spherical nanoparticles were observed without 
the presence of micrometer sized strands. However, doxHCl loading determination for 
these nanoparticles, using ones without any SOS incorporation as control, showed similar 
values (Table 2.6) with SOS-loaded nanoparticles actually having slightly lower drug 
loading (1.36% vs. 1.41%) and encapsulation efficiency (23.0% vs. 23.2%). This result 
was very surprising considering SOS should stay in the polymer phase and provide 
additional anionic charges for ion pairing with doxorubicin to reduce their loss from 
nanoparticles. A possible explanation for this could be due to the nature of the anionic 
sulfates. These sulfates were amphiphilic in nature, and as a result, they may 
preferentially localize to the surface of nanoparticles where the hydrophobic carbon chain 
portion intercalate into the polymer core while the hydrophilic sulfate portion orient 
toward the outer aqueous phase. During nanoparticle hardening, organic solvent 
movement/escape into bulk aqueous phase may facilitate movement of dissolved sulfate 
molecules toward nanoparticle surface and because of ion pairing between sulfates and 
doxorubicin, this could lead to drug loss (Fig. 2.8). 
2.5 Conclusions 
 
 To the best of our knowledge, this is the first time that doxorubicin hydrochloride 
has been modified into hydrophobic ion pair with small molecule alkyl sulfates for 
encapsulation into polymeric nanoparticles. Direct observations demonstrated drug 
complex formation while solubility and partition coefficient studies showed increasing 
hydrophobicity of these complexes. Doxorubicin sulfate complexes did not significantly 
change cell cytotoxicity (molar EC50 measurement) relative to free doxHCl, suggesting 
that it was the doxorubicin molecules, and not the complexes, that predominantly cause 
toxicity. 
 Despite improvements in hydrophobicity, low dissolution of the drug complexes 
in organic solvents commonly used for nanoparticle formulation precluded traditional 
 54 
 
formulation strategies. Alternative nanoparticle formulation methods also encountered 
significant obstacles for drug complex loading or showed no improvements relative to 
existing processes. 
 The above information demonstrated several important things. First, anionic 
sulfates were not appropriate ion pairing agents because even though hydrophobic drug 
complexes could form easily, their limited solubility in organic solvents precluded 
successful encapsulation. Second, their hydrophobicity, even though improved, was still 
relatively low and perhaps more hydrophobic versions of the sulfate molecules (even 
longer carbon chain) or a whole new class of lipophilic anions may be used to further 
improve drug hydrophobicity and loading into nanoparticles. Third, even though 
micrometer sized strands were obtained and could not be used for nanoparticle 
formulation, these products may be effective for alternative purposes such as microsphere 








































Table 2. 1. Alkyl sulfates tested as hydrophobic ion pairing agents with doxorubicin 
hydrochloride 












Sodium octyl sulfate 
(SOS) 
C8H17O4SNa 232.28 100 1.44 
Sodium dodecyl sulfate 
(SDS) 
C12H25O4SNa 288.38 8 3.6 
Sodium tetradecyl 
sulfate (STS) 
C14H29O4SNa 316.44 1.6 4.55 
Sodium octadecyl 
sulfate (SODS) 
C18H37O4SNa 372.55 0.45 6.03 
1. Colloids & Polymer Sci. 1984, 262: 657-661 





































Table 2. 2. Drug complex solubility data for various drug complexes and doxHCl after 12 
hours of incubation 
Concentration (mM) Drug or Drug 
Complex in PBS in DIW 
doxHCl 1.41 ± 0.01 ND 
#
 
doxSOS 0.41 ± 0.02 1.30 ± 0.30 
doxSDS 0.039 ± 0.001 0.029 ± 0.002 
doxSTS 0.014 ± 0.000 0.010 ± 0.001 
doxSODS 0.044 ± 0.000 0.011 ± 0.001 
#





































Table 2. 3. Partition coefficients of doxorubicin hydrochloride from organic (methylene 
chloride) to an aqueous (PBS) phase at equilibrium 
Drug Complex Partition Coefficient (P MC/PBS ± S.D.) 
doxSOS 0.33 ± 0.09 
doxSDS 1.34 ± 0.41 
doxSTS 0.82 ± 0.16 








































Table 2. 4. EC50 values for doxHCl or drug complexes from 48 h dose-response curve (n 
= 5). Measurements were done using SigmaPlot software to find the best-fit curve 
DoxHCl / Dox 
complex 
MW (g/mol) 
EC50-48 h (µg/ml ± 
Std. Err.) 
EC50-48 h 
(µM ± Std. Err.) 
doxHCl 580 0.12 ± 0.02 0.21 ± 0.03 
doxSOS 812 0.27 ± 0.02 0.33 ± 0.03 
doxSDS 868 0.28 ± 0.04 0.24 ± 0.03 
doxSTS 896 0.21 ± 0.03 0.23 ± 0.04 






































Table 2. 5. Solubility of different sulfates in methanol, acetone, or acetonitrile (STS and 
SODS are known to have low solubility in these organic solvent) 
Sulfate detergent Solvent Solubility 
1 mg SDS 0.1 or 0.2 ml methanol Insoluble 
1 mg SDS 0.1 or 0.2 ml acetone Insoluble 
1 mg SDS 0.1 or 0.2 ml acetonitrile Insoluble 
1 mg SOS 0.1 or 0.2 ml acetone Insoluble 







































Table 2. 6. DoxHCl loading and encapsulation efficiency for nanoparticles with and 








W/O/W-doxHCl 6.07 1.41 23.2 
W/O/W-doxHCl and 
SOS 








































































Sodium Octyl Sulf ate ( SOS) - C8H17NaO4S
Sodium Dodecyl Sulf ate ( SDS) - C12H25NaO4S


































Figure 2. 1. Structures of doxorubicin hydrochloride and the 4 sulfate-based anions and a 





















Figure 2. 2. Overlay of 
1
H-NMR spectra of free doxHCl and collected dox-sulfate 

















































Figure 2. 3. Dose-response curve showing inhibition of growth of K562 cells by different 
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Dialyze nanoparticles 



















































Figure 2. 6. SEM images of blank polymer nanoparticles without drug or sulfate 








































































Figure 2. 8. Schematic drawing of potential doxHCl loss from nanoparticles during 
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Systematic Study of Important Variables in Absorption Drug Loading into Specially 






 An effective drug loading procedure should be simple and time-efficient to 
maximize drug loading or uptake; adsorption drug loading, when optimized, could 
provide an important tool to fulfill these requirements. With this in mind, the purpose of 
this study was fourfold. First, evaluate the ion pairing potential between borate-based 
lipophilic anions and a model cationic drug, doxorubicin hydrochloride (doxHCl), in 
organic solvents, to introduce attractive force for absorption loading. Second, formulate 
blank polymeric nanoparticles incorporating borate-based lipophilic anions using oil-in-
water (O/W) emulsion for adsorption drug loading. Third, systematically study and 
optimize absorption loading of doxHCl into the aforementioned nanoparticles by 
analyzing different variables. Lastly, having optimized the drug uptake conditions, 
evaluate doxHCl uptake by nanoparticles in plasma.  
Results showed an almost 1:1 molar attraction between lipophilic anions and 
doxHCl as well as successful formulation of PLGA or PLGA/PEG-PLA polymeric 
nanoparticles incorporating one of the borates, potassium tetrakis(4-chlorophenyl)borate 
(KTpClPB). These nanoparticles were spherical and XPS confirmed the presence of PEG 
polymer on their surface. Adsorption drug loading was optimized using polymers with 
high acid number (502H), maximizing KTpClPB incorporation, increasing 
incubation/uptake temperature, increasing drug:nanoparticle incubation ratio, and using 
PEGylated nanoparticles (those containing PEG-PLA). Under optimized conditions, 
doxHCl loading reached as high as 6%. Studies with another model drug, vinblastine 
sulfate (VS), confirmed the utility of this loading procedure and specially formulated 
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nanoparticles. Plasma drug uptake study showed marginal reduction of plasma drug 
concentration at concentrations near the normal therapeutic dose of doxHCl while the 
nanoparticle system effectively reduced drug concentration by almost 16%, when plasma 
drug concentration was 4 times the normal therapeutic dose (200 µg/mL). Favorable 
results supported the use of borate-encapsulated polymeric nanoparticles for improved 




Nanoparticulate polymeric drug delivery systems have been the subject of intense 
research due to advantages including extended blood circulation time, improved passive 
or active drug targeting, reduced side effects and wasted drug, prolonged drug release for 
extended dosing intervals, and biocompatibility of different biodegradable polymers 
available for nanoparticle formulation (Soppimath, Aminabhavi et al. 2001; Yang, Wang 
et al. 2006; Park 2007).  
An important feature of these systems is drug loading, which may help to directly 
reduce total drug amount per dose and total dosing time while indirectly improving total 
release period as well as drug accumulation at target sites. For polymeric nanoparticles, 
many drug loading procedures have been established to improve loading of different 
drugs, each with their unique properties. Two commonly cited strategies are drug 
entrapment, where drug molecules are trapped in the hydrophobic polymer matrix of 
nanoparticles during formulation, and drug conjugation, where drug molecules are 
covalently linked to polymer strands before or after nanoparticle formulation. Three 
commonly cited entrapment methods are emulsification/solvent-evaporation, 
nanoprecipitation, and polymerization. Emulsification/solvent-evaporation method takes 
advantage of phase separation between oil and water to promote homogenization/ 
sonication-driven nanoparticle formation and examples include oil-in-water (O/W) or 
water-in-oil-in-water (W/O/W) emulsions. Nanoprecipitation method involves 
partitioning of water-soluble oil phase into an aqueous phase to promote emulsification 
without power input. The polymerization method, as the name suggests, is where 
nanoparticles are prepared through chemical polymerization of monomers (Soppimath, 
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Aminabhavi et al. 2001; Galindo-Rodriguez, Allemann et al. 2004). These different 
strategies differ in that each may be tailored to maximize loading of different types of 
drugs as well as facilitate the use of special polymers (Zobel, Zimmer et al. 1999; Krauel, 
Davies et al. 2005; Arias, Ruiz et al. 2008). Despite the effectiveness of entrapment 
methods, drug release from these nanoparticles have shown a large initial burst within the 
first 1-3 h of release and minimal release afterwards (Soma, Dubernet et al. 2000; Wong, 
Bendayan et al. 2004; Missirlis, Kawamura et al. 2006). To overcome this, drug 
conjugation can be utilized where drug molecules are chemically linked to polymer 
strands followed by use of these conjugates for particle formulation or linked to pre-
formed nanoparticles (Yoo, Oh et al. 1999). Even though zero-order drug release can be 
achieved through hydrolysis-limiting drug release, drug loading is low due to limited 
availability of conjugation sites.  
Another strategy now more commonly used to complement entrapment and 
conjugation loading methods is the absorption method, which, as the name suggests, 
achieves drug loading through incubation of blank nanoparticles with a concentrated drug 
solution (Asuri, Karajanagi et al. 2007; Arias, Linares-Molinero et al. 2008). This method 
originates from the need to encapsulate protein/peptide drugs into nanoparticles, where 
drugs could lose efficacy during stressful entrapment and conjugation loading procedures 
while the more passive adsorption loading process preserved drug integrity and efficacy. 
In studies cited thus far, the passive drug concentration gradient and potential 
hydrophobic interactions between the polymer and protein/peptide have played important 
roles in improving drug loading.  
Recently, the concept of ion pairing has been incorporated into nanoparticles 
undergoing adsorption loading. Here, electrostatic interactions are integrated into 
nanoparticles, by using charged polymers to formulate charged nanoparticles, to provide 
additional attractive forces with oppositely charged drug molecules. Examples of  the 
above strategy include using sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-
glycolide) to incorporated tetanus toxoid (Jung, Breitenbach et al. 2000), poly(ε-
caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) to enhance human basic 
fibroblast growth factor incorporation (Gou, Huang et al. 2007)and using poly(styrene-
co-4-styrene-sulfonate) to enhance lysozyme loading (Cai, Bakowsky et al. 2008). 
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Existing absorption drug loading procedures incorporating ion complexation or 
ion pairing, despite their effectiveness, still has several shortcomings. One is that charged 
polymers may be difficult to synthesize, purify, and characterize. Second, the potential 
utility of absorption loading for small molecule drugs, especially cationic anti-cancer 
drugs such as doxorubicin hydrochloride and vinblastine sulfate, have not been 
systemically evaluated, especially compared to existing ones. Third, no existing studies 
have evaluated the effectiveness of PEGylated nanoparticles, those with a layer of 
hydrophilic poly(ethylene glycol) (PEG) polymer on the surface, for absorption drug 
loading. Lastly, alternative uses of charged polymeric nanoparticles have not been 
explored. 
With the above issues in mind, there are several goals for this study. First, 
evaluate the ability of borate-based lipophilic anions to extract a model cation drug, 
doxorubicin hydrochloride, from aqueous to the organic phase. Second, a new anionic 
polymeric nanoparticle will be formulated using an FDA-approved polymer, PLGA, and 
borate-based lipophilic anions and properties such as borate incorporation, particle size 
and morphology will be evaluated. Third, absorption loading of doxHCl by the specially 
formulated nanoparticles will be studied systemically to optimize loading. Fourth, 
PEGylated nanoparticles will be formulated to evaluate its absorption drug uptake 
potential. Lastly, drug uptake in plasma will be explored to evaluate alternative uses for 
this nanoparticle system. 
3.3 Materials and Methods 
3.3.1 Materials 
 
Potassium tetrakis(2-thienyl)borate (KTTB), potassium tetrakis(4-
chlorophenyl)borate (KTpClPB), and potassium tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate (KTBTFMPB) were purchased from Sigma-Aldrich. 
Sodium tetraphenylborate (NaTPB) was a kind gift from Dr. Mark Meyerhoff. 
Doxorubicin hydrochloride (doxHCl) (>99% purity, lyophilized powder) was purchased 
from Hisun Pharmaceuticals (China). Poly(D,L-lactide-co-glycolide), 50/50, with 
inherent viscosity of 0.2 dl/g and MWw of 15 kDa (resomer 502H), 0.34 dL/g and MWw 
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of 38 kDa (resomer 503H), and 0.42 dL/g and MWw of 45 kDa (resomer 503), were 
purchased from Boehringer Ingelheim. Poly(vinyl alcohol) (PVA) with MWw of 25,000 
(88% hydrolyzed) was purchased from Polysciences Inc. L-lactide (>99% purity) was 
purchased from Sigma-Aldrich. Methoxy-poly(ethylene glycol) (mPEG-NH2, MWw = 
5,000) was purchased from Nektar Therapeutics. Spectra/por 7 dialysis bags (MWCO: 
10-12K or 50K, Spectrum) were purchased from Fisher Scientific All other chemicals 
and solvents were of analytical grade and purchased from commercial suppliers. 
3.3.2 Borate solubility 
 
Borates were weighed into glass tubes followed by addition of different organic 
solvents in 0.5 mL incremental volumes at room temperature. After shaking for 30 s, 
solubility was determined as the concentration when the solution was completely clear.  
3.3.3 DoxHCl extraction into borate-dissolved ethyl acetate phase 
 
DoxHCl was dissolved in deionized water (DIW) at 1.72 mM. KTTB, KTpClPB, 
and KTBTFMPB were dissolved in ethyl acetate at 0.5:1, 1:1, or 2:1 molar ratios with 
doxHCl. For extraction, 1 mL of either blank or borate-dissolved ethyl acetate solution 
was added to 1 mL doxHCl solution followed by vortexing for 30 s and shaking for 10 
min. The mixture was centrifuged at 5,000 RPM for 5 min, and the doxHCl concentration 
in the aqueous phase before and after extraction was determined by HPLC (see below). 











3.3.4 DoxHCl concentration determination methods 
 




A Waters HPLC system (Waters, Milford, MA) was used for chromatographic 
separation of doxHCl. It consisted of a 1525 Binary HPLC pump, 717 plus autosampler, 
and 474 scanning fluorescence detector. Waters Breeze
®
 chromatography software was 
used to acquire and process data. A Waters Nova-Pak
®
 C18 column (3.9 x 150 mm I.D.) 
(Waters, Milford, MA) was used with a filtered and degassed ACN : 20 mM, pH 3 
potassium phosphate : TFA (30:70:0.1, v/v/v) mobile phase. Chromatography was 
performed at a flow rate of 1 mL/min and fluorescence detection was set at λexcitation of 
480 nm and λemission of 590 nm at room temperature. 
DoxHCl in the samples were analyzed using corresponding standards injected 
separately. 
3.3.4.2 UV method 
 
A Beckman DU650 spectrophotometer was used for UV analysis. Samples or 
standards containing doxHCl in methanol were analyzed using a quartz 
spectrophotometer cell (Starna Cells Inc.) at a scanning rate of 1200/min and scanning 
range of 400-750 nm. Absorbance wavelength was set at 480 nm and all sample had 
baseline reading set at 750 nm.  
3.3.5 PEG-PLA copolymer synthesis and characterization 
 
Methoxy-poly(ethylene glycol)-poly(lactic acid) (PEG-PLA) was synthesized by 
a standard ring opening polymerization. Briefly, L-lactide (Sigma, 98% purity) was pre-
purified by recrystallization from ethyl acetate and the catalyst, stannous octoate (Tin(II) 
2-ethylhexanoate, Sigma, 95% purity), was pre-purified by distillation. The desired molar 
ratio of L-lactide to mPEG-NH2 was weighed out and added to the reaction flask 
followed by addition of stannous octoate at equivalent molar ratio to mPEG-NH2. Dry 
toluene (10 mL / 1.5 g of reactants) was added to dissolve and mix the reagents. The 
reaction proceeded with stirring at 110
o
C for 2 hours under moisture-free argon 
atmosphere. At the end of the polymerization step, copolymer was purified and recovered 
as follows. The copolymer crystallized upon cooling and was dissolved with cooled 
dichloromethane followed by ether addition to reprecipitate the copolymer. The previous 
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procedure was repeated and the copolymer was collected by filtration on a Buchner 
funnel. They were then dried at 37
o
C in a vacuum oven overnight.  
PEG-PLA was analyzed by 
1
H-NMR spectroscopy using a Bruker DRX 500 
spectrometer (Bruker Biospin Inc., Billerica, MA) operating at 500 MHz. Peak areas for 
different hydrogens were used for PEG-PLA molecular weight determination. 
3.3.6 General nanoparticle formulation 
 
Nanoparticles were formulated using an oil-in-water (O/W) emulsion/solvent 
evaporation procedure (Fig. 3.6). Different amounts of polymer were dissolved in 2 mL 
ethyl acetate (oil phase) and emulsified by sonication (20 s) on ice using a probe 
sonicator (Sonics VibraCell) at 50% power in 2 mL 3% PVA solution (aqueous or water 
phase). The O/W emulsion was diluted into 40 mL of 0.075% PVA solution under rapid 
magnetic stirring for 4-5 hours. Nanoparticle suspensions were collected and washed 
using an Amicon Stirred Cell with a 50 nm Millipore nitrocellulose filter.  
KTpClPB-loaded nanoparticles were formulated using the same O/W procedure 
above except that predetermined amounts of KTpClPB were dissolved in the ethyl acetate 
phase along with polymer. 
PEGylated nanoparticles were formulation using the same O/W procedure above 
with modifications. 502H PLGA and KTpClPB were dissolved in 2 mL ethyl acetate and 
mixed with PEG-PLA dissolved in 0.2 mL methylene chloride. This oil phase was 
emulsified in 2.2 mL of 3% PVA solution. All other steps were unchanged. 
3.3.7 Nanoparticle characterization 
3.3.7.1 Particle size/zeta potential determination 
 
Nanoparticle suspensions were diluted to 0.5 mg/mL and transferred into fold 
capillary cells for both zeta potential and particle size determination. Samples were 
analyzed using a Malvern ZetaSizer Nano ZS (Malvern Instruments). 




Nanoparticle suspensions were diluted to 50 µg/mL and dried overnight on 
viewing stubs. Morphology was observed by scanning electron microscopy (Philips 
XL30 Field Emission Gun Scanning Electron Microscopy). 
3.3.7.3 Surface chemistry analysis 
 
 Surface chemistry of nanoparticle with or without PEG-PLA (no drug loaded) as 
well as PEGylated nanoparticles with doxHCl loaded was characterized by X-ray 
photoelectron spectroscopy (XPS, Kratos Axis Ultra, Kratos Analytical) equipped with a 
monochromatized aluminum X-ray source (powered at 10 mA and 14 kV). The angle 
between the normal to the sample surface and the lens axis was 0O. A survey scan 
spectrum (0-1000 eV, average of 4 scans) and regional scan for C1s (265-295 eV, average 
of 10 scans) were recorded for each sample. The analyzer was set at pass energies of 160 
eV or 20 eV for the survey or regional scans, respectively. Analysis of data was done 
with CasaXPS program (Casa Software Ltd., UK) with a Gaussian/Lorentzian product 
function. Chemical shifts for the C1s regional scans were referenced to hydrocarbon at 
285 eV.  
3.3.8 KTpClPB loading determination 
 
KTpClPB was extracted from nanoparticles by adding 0.1 mL methylene chloride 
followed by 1.5 mL methanol to pre-weighed nanoparticle powder. The suspension was 
shaken overnight for complete extraction and spun down at 13,200 RPM for 8 minutes. 
Supernatant containing KTpClPB was diluted 4-fold by addition of methanol and sample 
concentration was determined using HPLC with corresponding standards injected 
separately.  
Waters HPLC system (Waters, Milford, MA) was used. It consisted of a 1525 
Binary HPLC pump, 717 plus autosampler, and 2487 Dual λ absorbance detector. Waters 
Breeze
®
 chromatography software was used to acquire and process data. No column was 
used. Chromatography was performed using 100% acetonitrile as the mobile phase, at a 




3.3.9 General drug absorption loading into nanoparticles 
 
Drug was dissolved to desired concentrations in deionized water (DIW). Both the 
drug solution and a nanoparticle suspension (known concentrations) were added 
consecutively into an aqueous phase so that 1) drug and nanoparticle reached desired 
concentrations and relative weight ratios and 2) final suspension volume reached 4 mL. 
Mixtures were shaken (Ika KS130) for different lengths of time at different temperatures.  
 After drug loading, mixtures were dialyzed in Spectra/por 7 dialysis bag (MWCO: 
50,000, Spectrum) against 1 liter of DIW (replaced every hour during the first 3 h) over 
24 h. Dialyzed suspensions were used for size, zeta potential, and drug loading 
determination. 
3.3.10 Drug loading determination 
 
This procedure is similar to KTpClPB loading determination. Briefly, drug loaded 
nanoparticle samples were lyophilized and weighed into 2 mL polypropylene tubes. 0.1 
mL methylene chloride was added to nanoparticles, followed by shaking for 10 min, then 
addition of 1.5 mL methanol and shaking for over 12 h. These suspensions were spun 
down at 13,200 RPM for 8 min. Supernatant containing dissolved drug was diluted as 
appropriate using methanol. Drug concentration was analyzed using UV doxHCl 
concentration determination procedure above. 
3.3.11 Vinblastine sulfate uptake study 
 
 Two types of nanoparticles were used for this study. 502H:PEG-PLA(7:1, wt/wt) 
mixed polymeric nanoparticles with or without incorporation of maximal amount of 
KTpClPB in the organic phase formulated at total polymer concentration of 20 mg/mL in 
ethyl acetate. Different nanoparticle formulations were loaded with vinblastine sulfate 







Formulation Drug uptake temperature (
o
C) KTpClPB presence 
1 Room temp No 
2 37 No 
3 37 Yes 
The above table describes the three groups of nanoparticles incubated with vinblastine 
sulfate. Nanoparticles were mixed polymeric nanoparticles with 20 mg/mL polymeric 
concentration in ethyl acetate. 
 
 For the incubation drug uptake procedure, 7.5 mg of blank nanoparticles were 
mixed with 1.5 mg of VS in a total of 4 mL DIW and incubated at different temperature, 
with shaking, for 30 min. Drug loaded nanoparticles were dialyzed (spectra/por 7, 
MWCO: 50K) against 1 L of DIW (replaced every hour for the first 3 h) over 24 h. 
Nanoparticles were lyophilized and then weighed out. VS was extracted from 
nanoparticles by adding 0.1 mL methylene chloride and 1.5 mL methanol to pre-weighed 
nanoparticles followed by shaking for 12 h. The suspension was spun down and 
supernatant containing VS was injected into HPLC for concentration determination. 
 A Waters HPLC system used for doxHCl detection was also used for VS 
detection. No HPLC column was used and the mobile phase was methanol:10 mM 
sodium phosphate (60:40). Flow rate was 1 mL/min and injection volume was 100 µL. 
UV detection was set at 270 nm and VS in the samples were analyzed using 
corresponding standards injected separately. 
3.3.12 Plasma drug extraction procedure 
 
Goat plasma was aliquoted into 36 – 3 mL portions and divided into 12 groups of 
3 portions each. Into six of the groups (control groups), 10 mg/mL doxHCl solution was 
added to plasma to reach either 15 µg/mL, 30 µg/mL, 50 µg/mL, 100 µg/mL, 150 µg/mL, 
or 200 µg/mL followed by addition of 25 µL of deionized water (DIW). Into the 
remaining six groups, 10 mg/mL doxHCl was added to reach the above concentrations 
followed by addition of 25 µL (0.95 mg) of blank PEGylated nanoparticle suspension. 
The 12 groups were shaken at 37
o
C for 30 minutes. Six groups containing 
nanoparticles were first centrifuged at 21,000 RPM for 25 minutes to spin down the 
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nanoparticles; supernatant samples were transferred to labeled tubes. 0.4 mL of plasma 
from each sample in each group was transferred into 15 mL polypropylene tubes 
followed by addition of 4 mL methanol:chloroform (3:1, v/v), 1 minute vortexing, and 
shaking for 10 minutes. Samples were then centrifuged at 12,000 RPM for 10 minutes 
and 2 mL of the organic phase was transferred into 50 mL polypropylene tubes and dried.  
Dried phase was reconstituted using 0.3 mL methanol (for 15 – 100 µg/mL 
doxHCl samples) or 0.6 mL methanol (for 150 and 200 µg/mL doxHCl samples) and 
drug concentration was analyzed using HPLC (with no column) with corresponding 
standards injected separately. 
3.4 Results and Discussion 
3.4.1 Borate selection and properties 
 
 Borate-based lipophilic anions have traditionally been utilized as exchangers in 
ion-selective electrodes (Ganjali, Norouzi et al. 2006; Gupta, Singh et al. 2008). For this 
reason, different properties for these anions, relevant for nanoparticle encapsulation, 
either have not been studied or have not been published. For this project, two critical 
properties of borates were logP, or partition coefficient of the anions between 
hydrophobic and hydrophilic phases, and solubilities in different organic solvents. The 
former could give a rough estimate of compatibility of these anions with hydrophobic 
cores of nanoparticles while the latter may suggest solvents appropriate for nanoparticle 
formulation. For borate-based compounds in this study (Fig. 3.2), logP values were 
obtained as estimates using ChemDraw program (Table 3.1) and their solubilities in 
different organic solvents were determined by incremental addition of organic solvents to 
each borate compound (Fig. 3.2). 
 Borate anions demonstrated increasing logP values (increasing hydrophobicity), 
which indicated good hydrophobicity and compatible with nanoparticle cores (Fig. 3.2, 
Table 3.1). With addition of halogen and carbon atoms to the aromatic rings of the 
borates, hydrophobicity increased dramatically and could suggest design patterns which 
may be helpful when synthesizing new biocompatible lipophilic anions more appropriate 
for human usage. There did not appear to be a correlation between increasing logP values 
 82 
 
and solubility in organic solvents (Table 3.1, Fig. 3.3). KTTB was not soluble in any 
organic solvents tested and was not studied. For polymeric nanoparticle formulations, the 
most commonly used organic solvents for preparation are methylene chloride, chloroform, 
and ethyl acetate. Because methylene chloride and chloroform dissolved the borates very 
poorly, ethyl acetate, which dissolved the borates up to 2.5 mg/mL, was chosen as the 
organic solvent for nanoparticle preparation. 
3.4.2 DoxHCl extraction by borate molecules 
 
  Knowing that borates could dissolve in ethyl acetate, it was important to show 
that they could also extract a model hydrophilic drug, doxorubicin hydrochloride 
(doxHCl), from aqueous to the ethyl acetate phase. By itself, doxHCl had negligible 
solubility in ethyl acetate (Fig. 3.4A) and could not be extracted, but with increasing 
amounts of borates in the ethyl acetate phase, doxHCl extraction improved significantly 
(Fig. 3.4B). Quantitatively, doxHCl extraction was 93.4% for NaTPB, 97.0% for 
KTpClPB, and 94.9% for KTBTFMPB at 1:1 molar ratio of borate to drug (Fig. 3.5). 
This suggested the extraction process was primarily due to electrostatic interactions 
between anionic borates and cationic drug molecules and demonstrated the potential for 
doxorubicin to enter hydrophobic cores of borate-loaded nanoparticles. 
 Previous studies using NaTPB as ion exchangers showed leaching of the 
electrostatically bound material, suggesting it was not the best borate for future studies; 
while KTBTFMPB was 20 times more expensive than the other borate anions. For the 
above reasons, KTpClPB was chosen as the model lipophilic anion for nanoparticle 
studies. 
3.4.3 Nanoparticle formulation with encapsulated KTpClPB 
 
 KTpClPB has not been associated with nanoparticle formulations in previous 
publications. For this study, an oil-in-water (O/W) emulsion method was used to 
formulate KTpClPB-loaded polymeric nanoparticles (Fig. 3.7). Because both the polymer 
chosen, PLGA, and the borate-based anion, KTpClPB, could dissolve in ethyl acetate, the 
procedure was simple as ethyl acetate with dissolved KTpClPB and PLGA was 
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emulsified into an outer aqueous phase to formulate the particles. To validate successful 
nanoparticle formation, particle sizing was done to determine the number and size of 
nanoparticle population(s) and scanning electron microscopy (SEM) was done to observe 
the morphology of the nanoparticles. The results were positive as particle size (not shown 
here) showed a unimodal (one population or peak) distribution with an average size 
below 200 nm depending on the initial amounts of KTpClPB added and SEM images 
(Fig. 3.8) showed spherical nanoparticles with similar sizes range of between 100-250 nm. 
3.4.3.1 KTpClPB presence and quantification in nanoparticles 
 
 Despite a monomodal size distribution, direct evidence of KTpClPB incorporation 
into the nanoparticles was still needed and two other experiments were done to confirm 
its incorporation. First, the O/W emulsion procedure was repeated except that only 
KTpClPB, and no polymer, was dissolved in the ethyl acetate phase. The resulting 
emulsion was clear, filtered through the stir cell membrane filter system (used for 
washing nanoparticles) rapidly unlike nanoparticle suspensions with KTpClPB 
encapsulated, which did not filter through at all. This demonstrated that any KTpClPB 
not encapsulated into nanoparticles would be removed from the nanoparticle solution 
during the washing procedure and any changes in particle size or drug loading for 
KTpClPB-loaded versus KTpClPB-free nanoparticles was due to KTpClPB actually 
associated with nanoparticles. Second, and more importantly, KTpClPB was extracted 
from lyophilized nanoparticles with 0 or 10.7% theoretical KTpClPB loading (Table 3.2). 
HPLC analysis of extracted supernatant from KTpClPB-loaded nanoparticles showed a 
large peak which was not present for extracted supernatant of KTpClPB-free 
nanoparticles. Another important result from this HPLC experiment was that incubation 
of KTpClPB-loaded nanoparticles in different solutions (PBS or DIW) for 1 h or less did 
not appear to cause KTpClPB loss as calculated percent loading results for non-incubated 
and incubated nanoparticles were similar. In addition, it was observed that only 40% of 
the initial KTpClPB added was actually encapsulated (Table 3.2), which suggested an 
upper limit on how much KTpClPB could actually be incorporated. The above results 
clearly demonstrated encapsulation of KTpClPB into the nanoparticles although more 
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than half of the KTpClPB was lost during formulation. This experiment, however, did not 
show the location of these molecules in nanoparticles (core or surface or both). 
3.4.4 Optimization of incubation drug loading 
 
 Under optimal conditions, absorption drug loading, where drug is incubated with 
and extracted into pre-formulated nanoparticles, may prove to be a versatile strategy to 
improve drug loading and other properties using PLGA-based nanoparticles. To optimize 
these conditions, various factors were analyzed including 1) PLGA acid number, 2) 
increasing KTpClPB loading, 3) impact of temperature, 4) different weight ratios of 
nanoparticles to drug in the incubation media, and 5) impact of PEGylation of 
nanoparticles.  
3.4.4.1 Polymer (PLGA) selection 
 
 Many different polymers have been specially synthesized for the purpose of 
absorption drug loading, however, PLGA, the most readily available polymer approved 
by the FDA for clinical use, has not been systemically studied for absorption 
loading/uptake purposes much less in combination with KTpClPB. For this study, three 
different PLGA 50/50 polymers were selected (Table 3.3) to formulate blank 
nanoparticles (no KTpClPB added) to isolate the property most important for choosing 
the best PLGA. Of the three, 502H had the smallest molecular weight and viscosity, 
indicating that nanoparticles formulated using this polymer should be smaller than 
particles formulated using the more viscous polymers. More importantly, the acid 
numbers of the polymers were quite different. Resomer 503 was end-capped with acid 
number of  <1, meaning the majority of carboxylic acid groups at the end of each 
polymer strand were “capped” by an alkyl group to form alkyl esters. Because carboxylic 
acid groups could contribute negative charges for electrostatic attraction to cationic drugs, 
the polymer with the highest acid number, resomer 502H, was expected to produce 
nanoparticles with the highest drug loading. Results confirmed this hypothesis as 502H 
nanoparticles (ethyl acetate organic phase) showed substantially higher extraction 
efficiency and drug loading (Fig. 3.10A) relative to nanoparticles made with other 
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polymers, reaching 1.44% drug loading and 44.6% extraction efficiency. In comparison, 
nanoparticles formulated using resomer 503, the end-capped PLGA, showed negligible 
drug loading of 0.09% loading and 2.8% extraction efficiency (Fig. 3.10B), which was 
expected considering they are end-capped. Another interesting result from this figure was 
that resomer 503H nanoparticles made with ethyl acetate organic phase, which were 
smaller than ones made with methylene chloride, had twice the drug loading and 
significantly improved encapsulation efficiency. 
The results confirmed that acid number was important for enhancing drug loading 
and encapsulation efficiency and polymers with highest acid number should be selected 
while smaller particles, with greater surface area-to-volume ratio and potentially higher 
polymer density, was also important for improving adsorption drug loading.  
3.4.4.2 KTpClPB incorporation 
 
 Even though anionic polymers or copolymers have been synthesized in the past to 
increase electrostatic interactions with cationic drugs, small molecule lipophilic anions 
such as KTpClPB have not been studied for this purpose and optimal amount of 
KTpClPB for nanoparticle incorporation was uncertain.  
As the data showed, increasing KTpClPB incorporation increased extraction 
efficiency (measure of how much drug initially present in the incubation media was taken 
up by the particles) from 48% to 75% at the highest KTpClPB loading, and drug loading 
from 3.0% without KTpClPB addition to 4.8% at maximal KTpClPB loading (Fig 3.11A). 
These results clearly demonstrated the benefits of lipophilic anions and also suggested 
that additional KTpClPB incorporation would continue to increase drug loading; however, 
since KTpClPB incorporation in this study was limited by its solubility in ethyl acetate, 
further improvements in drug uptake was unlikely.  
Previous results had shown approximately 40% encapsulation efficiency of 
KTpClPB into nanoparticles (Table 3.2). Based on this result, when maximal KTpClPB 
amount was loaded into nanoparticles (4.8 mg KTpClPB for 80 mg polymer 
nanoparticles), only 2.16 mg of KTpClPB was actually encapsulated in 80 mg of polymer 
nanoparticles. Since doxHCl loading was improved by 1.8% (3% to 4.8% as stated above) 
due to maximal KTpClPB addition, this meant an additional 1.44 mg of doxHCl was 
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loaded for every 80 mg of polymer in nanoparticles due to KTpClPB presence. Together, 
2.16 mg KTpClPB and 1.44 mg doxHCl meant a KTpClPB:doxHCl molar ratio of 1.75:1, 
which suggested not all the encapsulated KTpClPB was paired with a drug molecule and 
anionic charges were still available. However, KTpClPB may be buried deep within the 
nanoparticles, precluding drug access. Furthermore, the results did not clearly indicate if 
hydrophobic interactions (pi-pi stacking) played a factor in the increased drug loading.  
Another interesting observation was that in the presence of increasing KTpClPB, 
nanoparticle size decreased dramatically from 182.5 nm to 117.1 nm (Fig. 3.11B). One 
hypothesis for this was that increasing KTpClPB may lead to more drug loading and 
more hydrophobic drug-KTpClPB ion pair formation, especially on particle surface. 
These hydrophobic ion pairs could drive water away from, or even out of, nanoparticles 
and lead to a smaller hydrodynamic radius recognized by the particle sizing instrument. 
3.4.4.3 Temperature effect on adsorption uptake 
 
 With increasing KTpClPB loading into 502H nanoparticles, doxHCl loading and 
extraction efficiency could be improved significantly, as results showed. Even though the 
previous KTpClPB uptake studies were done at 37
o
C, the physiological temperature, it 
was important to discern the effects of temperature on drug loading and extraction 
efficiency. Comparison of drug adsorption loading for KTpClPB-loaded nanoparticles at 
room and physiological temperatures showed a very interesting trend where all other 
conditions being equal, higher temperature generated approximately 30% higher drug 
loading at all KTpClPB loadings (Fig. 3.12A) as well as similar increases in extraction 
efficiency (data not shown). For example, drug loading for nanoparticles with no 
KTpClPB incorporated improved from 1.4% to 3.0% while nanoparticles with 
maximized KTpClPB loading improved from 3.7% to 4.8%. These data demonstrated 
temperature-dependent drug loading improvement was actually due to the polymer used 
(502H) themselves rather than because of KTpClPB. A hypothesis for this increase 
focused on polymer rearrangement in nanoparticles. Polymeric nanoparticles could be 
envisioned as a ball of polymer strands with each strand having random motion. 
Hydration of nanoparticles and residence in an environment where temperature was 
above the glass transition temperature (Tg) for the polymer were known to significantly 
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increase the polymer strand motion and lead to rearrangement within a nanoparticle. For 
PLGA, an experimentally determined Tg value was approximately 31
o
C (Blasi, D'Souza 
et al. 2005), which was in between the room temperature and physiological temperatures 
studied and led to the conclusion that in this case, increasing polymer rearrangement due 
to temperature increase led to increased drug molecule partitioning into the polymer 
phase and ion-pair formation with polymer carboxylic acids and KTpClPB. This 
phenomenon was also cited in a previous article from Kang and colleagues (Kang and 
Schwendeman 2003), where partitioning of small hydrophobic probes into polymer films 
increased with increasing temperature.  
3.4.4.4 Effect of drug:nanoparticle ratio on drug uptake 
 
 For absorption loading, relative amounts of nanoparticle and drug in solution 
could be important due to a passive drug concentration gradient. However, it was 
uncertain how much KTpClPB presence could impact this and at what drug:nanoparticle 
weight ratio further increases in drug amount would make no difference. 
 For this study, fixed amount of KTpClPB-loaded nanoparticles were incubated 
with increasing amounts of doxHCl in solution up to 1.5 mg. However, at the highest 
ratio of 1.5 mg:15 mg (drug:nanoparticle), nanoparticle aggregation and sedimentation 
occurred during incubation. Between additions of 0.25 mg to 1 mg doxHCl, though, 
results (Fig. 3.13A) showed almost complete doxHCl extraction efficiency (95% or 
above) with 0.25 mg or 0.5 mg doxHCl in solution and 75% when 1 mg doxHCl was 
present. Drug loading also increased from 1.6% (with 0.25 mg doxHCl added) to 4.8% 
(with 1 mg doxHCl added); this was logical given the higher drug concentration gradient 
explained before and higher driving force for partitioning into nanoparticles. 
Nanoparticle zeta potential was more positive with drug adsorption loading (changing 
from -35 mV to ~ -26 mV), which was reasonable considering surface negative charges 
were being neutralized; however, there was no significant change in zeta potential nor 
particle size with increasing amounts of drug (0.25 mg – 1 mg) in the incubation media 
(Fig. 3.13B). This suggested that additional loaded drug were below the top layer of 




Drug loading versus amount of doxHCl added curve increased in an almost linear 
fashion without reaching a plateau, suggesting that not all potential drug binding sites 
were occupied on nanoparticles and higher loading could be achieved if nanoparticle 
aggregation problem could be resolved.  
3.4.4.5 PEGylated nanoparticles 
 
 Traditionally, it was known that hydrophilic moiety (polymer) could be grafted 
onto nanoparticle surface to form a hydrophilic surface layer that repels protein 
adsorption onto nanoparticle surface as well as reduce potential aggregation between 
particles. A commonly used hydrophilic polymer for this purpose is poly(ethylene glycol) 
(PEG) (Heald, Stolnik et al. 2002), a biodegradable polymer used in commercial products. 
For formulation purposes, PEG was usually incorporated through direct conjugation to a 
hydrophobic polymer, such as poly(lactic acid) (PLA), to form a diblock copolymer, 
which may be used by itself or in combination with other polymers to form nanoparticles. 
As copolymer nanoparticles form, PLGA or PLA segment intertwine to form a 
hydrophobic nanoparticle core while the hydrophilic PEG segments extend out to form a 
hydrophilic shell (Fig. 3.14). 
3.4.4.5.1 NMR characterization 
 
 Here, PEGylated nanoparticles were made from a mixture of resomer 502H and 
synthesized PEG-PLA although the total polymer concentration for these PEGylated 
nanoparticles was the same as regular nanoparticles made with only resomer 502H. NMR 
spectrum of the copolymer (Fig. 3.6A) matched those in previously published papers 
(Olivier, Huertas et al. 2002) and based on comparison of the various peaks obtained, 
calculated molecular weights of between 19,408 – 22,689 Da were obtained which was 
similar to the theoretical value of 25,000 Da found based on the weight ratio of L-lactide 
and mPEG-NH2 used to synthesize the copolymer (Fig. 3.6B). 




 X-ray photoelectron spectroscopy (XPS) has been used extensively for surface 
analysis of various polymeric materials. Using this technique, binding energies of 
electrons associated with different atoms in the top 2-10 nm of a surface can be measured 
to collect elemental and chemical information (Scholes, Coombes et al. 1999; Dong and 
Feng 2004). Here, XPS was utilized to analyze six nanoparticle samples including 1) 
blank PLGA (502H), 2) blank PEG-PLA, 3) blank PLGA:PEG-PLA (7:1, wt/wt) 
nanoparticles, all without KTpClPB addition; as well as 4) blank PLGA (502H), 5) blank 
PLGA:PEG-PLA (7:1, wt/wt), and 6) doxorubicin-loaded PLGA:PEG-PLA (7:1, wt/wt), 
all 3 of which had maximal KTpClPB incorporation. These samples were investigated for 
chemical composition as well as the presence of doxHCl and PEG polymers on 
nanoparticle surface. 
 Survey scans of the nanoparticle samples (Fig. 3.15) were done to detect carbon, 
oxygen and nitrogen atoms on nanoparticle surface and their percent composition. Of the 
materials present in nanoparticles, only the drug, doxorubicin hydrochloride (doxHCl), 
contained nitrogen atoms in its structure, thus presence of nitrogen peak at around 400 eV 
in the survey scans would indicate drug accumulation on nanoparticle surface. However, 
all six survey scans were similar in shape and showed visible C1s and O1s peaks, while no 
nitrogen peaks were present. Quantification results further confirmed this as all six 
samples, with the exception of blank KTpClPB-loaded PLGA (502H) nanoparticles, had 
zero nitrogen content (Table 3.4). Because the detection limit of this instrument is 0.1%, 
though, even the 0.1% nitrogen composition for blank KTpClPB-loaded PLGA 
nanoparticles was negligible. Upon analysis, this result was expected because based on 
the chemical formula of doxHCl, C27H29NO11Cl, nitrogen has a theoretical percent 
atomic composition of 2.5% within doxorubicin; and when embedded into or onto 
nanoparticles, surrounded by numerous other carbon and oxygen atoms of polymers, this 
was easily reducible to less than 0.1%. From survey scan results, it was hard to draw 
conclusions regarding doxHCl localization within nanoparticles.  
A surprising result from the survey spectra was that the percent atomic 
composition of carbon was similar to that of oxygen (Table 3.4), different from a 
previous study showing a 2:1 atomic ratio of carbon:oxygen (Pourcelle, Devouge et al. 
2007), and different from predicted theoretical values of 2:1 for PEG, 2.5:2 for PLGA, 
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and 3:2 for PLA, all based on their respective chemical formulas. Considering that even 
the controls for this study, blank PLGA and blank PEG-PLA nanoparticles, both had low 
carbon:oxygen atomic ratios, this result could be due to a problem with instrument 
calibration where the intensity readings for the carbon peak was not fully optimized. 
From the atomic composition of carbon (Table 3.4), it was observed that carbon 
composition for blank PEG-PLA nanoparticles was 5% higher than blank PLGA 
nanoparticles (43.6% vs. 48.6%), which was expected given the higher theoretical 
carbon:oxygen ratio for PEG. Based on this, it was also not surprising to see blank 
PLGA:PEG-PLA nanoparticles with a percent carbon composition in between that of 
PLGA and PEG-PLA nanoparticles and this result was direct evidence of the presence of 
PEG strands on nanoparticle surfaces.  
 Results from Table 3.4 also showed that percent carbon composition for blank 
PLGA:PEG-PLA and blank PLGA/KTpClPB nanoparticles were similar (45.8% vs. 
45.4%). Because there were no PEG-PLA in the KTpClPB loaded nanoparticles, a 
potential explanation for the increased carbon composition was due to KTpClPB, which 
has an amphiphilic structure (Fig. 3.2) that promoted localization on nanoparticle 
surfaces (similar to detergents) as well as a number of benzene rings in its structure 
which contribute to percent carbon composition. However, another potential cause could 
be polyvinyl alcohol (PVA), a surfactant added to all six formulations that could localize 
to the surface of nanoparticles to stabilize them. Like PEG, PVA also has 2:1 
carbon:oxygen atomic ratio and the combinations of PVA + PEG-PLA and PVA + 
KTpClPB on nanoparticle surfaces could lead to similar carbon:oxygen ratios if enough 
PVA was present. 
Lastly, results showed percent carbon composition for blank PLGA:PEG-
PLA/KTpClPB and PLGA:PEG-PLA/KTpClPB/dox nanoparticles were significantly 
higher than the other four batches (Table 3.4). This result was surprising considering the 
magnitude of the increase relative to the control, blank PLGA nanoparticles (51.2 – 
52.1% to 43.6%, 7-9% increase). Blank PLGA:PEG-PLA and blank PLGA/KTpClPB 
nanoparticles each had approximately 2% higher carbon composition relative to blank 
PLGA nanoparticles, which meant a combined increase of 4%, or around 47.6% 
theoretical carbon composition for nanoparticles with both PEG-PLA and KTpClPB 
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added. However, actual carbon compositions were 51.2% and 52.1%, or between 3-5% 
higher than expected, for PLGA nanoparticles containing PEG-PLA and KTpClPB. This 
phenomenon could be due to synergistic actions between PEG-PLA and KTpClPB, 
which multiplied rather than simply added the contributions of the components, when 
both components were present in nanoparticles. For example, by itself, PEG-PLA was 
miscible with PLGA and the combination of the two on nanoparticle surface led to a 
lower carbon:oxygen ratio than if only PEG-PLA was present on the surface. However, 
the presence of KTpClPB on nanoparticles appeared to reduce this miscibility and caused 
PEG-PLA to be pushed to the surface of nanoparticles, away from the PLGA core. Thus 
the combination of PEG-PLA with KTpClPB, with its many benzene rings and carbon 
atoms, formed a thick enough layer on nanoparticle surfaces to increase percent carbon 
composition readings.  
 Decomposition of C1s envelope, based on previous studies (Shakesheff, Evora et 
al. 1997; Dong and Feng 2004; Pourcelle, Devouge et al. 2007), could further confirm the 
presence of PEG on nanoparticle surface (Fig 3.16). Ether carbons and hydrocarbons 
were primary constituents of PEG and ether carbons typically have a chemical shift of +1 
to +1.3 eV relative to hydrocarbons referenced at 285 eV. In this study, 10.35% carbons 
were present at 286.3 eV (where ether carbons would be) for blank PLGA nanoparticles 
even though PEG was not present (Table 3.5). The presence of these carbons was again 
due to PVA, which was used to formulate all six nanoparticle formulations and was 
present on nanoparticle surfaces as a particle-stabilizing emulsifier. PVA has a carbon 
backbone with a hydroxyl group linked to every other carbon atom; hydroxyl carbons 
have similar chemical shifts as ether carbons and caused the 10.35% reading. Relative to 
blank PLGA standard, blank PEG-PLA nanoparticles had increased percentages of 
hydrocarbons as well as PEG carbons, which was expected since both PEG and PVA in 
these nanoparticles could contribute both types of carbons.  
 It was found that blank PLGA:PEG-PLA nanoparticles had slightly more 
hydrocarbons and PEG carbons relative to blank PLGA nanoparticles (less than 1 percent 
each, Table 3.5). Based on the fact that instrument detection limit was 0.1% and PEG-
PLA only constituted 12.5% (wt/wt) of each nanoparticle, this again showed that some 
PEG was present on the surface layer. This result also matched previous percent carbon 
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composition results (Table 3.4), where blank PLGA:PEG-PLA nanoparticles had 
approximately 2% higher carbon composition relative to blank PLGA nanoparticles due 
to PEG presence. 
 Earlier, it was proposed that when both KTpClPB and PEG-PLA were 
incorporated into nanoparticles, PEG-PLA would have reduced miscibility with PLGA 
and PEG-PLA, along with KTpClPB, could form a surface layer that shielded the PLGA 
core. This was again confirmed through the carbon decomposition results (Table 3.5). For 
PLGA:PEG-PLA/KTpClPB nanoparticles with and without doxHCl, both hydrocarbons 
and PEG carbon percentages were much higher than polyester and carboxyl carbons, both 
of which were normally indicative of PLGA polymers. Furthermore, it was very 
interesting to see the PEG carbon percentages for these two nanoparticle formulations 
(32.79% and 34.20%) to be much higher than even blank PEG-PLA nanoparticles 
(18.04%) while polyester and carboxyl carbon percentages were much lower. This result 
indicated that the combination of KTpClPB with 12.5% weight percent PEG-PLA in 
PLGA nanoparticles may be a thicker layer than the PEG layer of pure PEG-PLA 
nanoparticles. 
 Lastly, an important observation from Table 3.5 was that PLGA:PEG-
PLA/KTpClPB nanoparticles, with doxorubicin loaded, contained 42.99% hydrocarbons, 
while the batch with no doxorubicin had 40.47% hydrocarbons. Because the structure of 
doxorubicin (Fig. 3.1) contained many fused rings with numerous C-C, C-H 
(hydrocarbon) carbons, the 2.52% increase in hydrocarbon reading could be attributed to 
the presence of doxorubicin. Even though it was nearly impossible to calculate the 
number of doxorubicin molecules representing this 2.52% increase, qualitatively, it was 
safe to say that part of the doxorubicin loaded into these nanoparticles via incubation 
loading was in the surface layer.  
3.4.4.5.3 SEM characterization 
 
SEM images showed PEGylated nanoparticles, like regular ones, were spherical 
with size range of between 100-200 nm (Fig. 3.18). To study potential improvements of 
PEGylated nanoparticles, increasing amounts of doxHCl were again incubated with fixed 
amount of PEGylated nanoparticles up to 2 mg doxHCl. Because results at 2 mg doxHCl 
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addition were almost the same as those at 1.5 mg doxHCl addition, these results were not 
shown. With increasing doxHCl addition to PEGylated nanoparticles, no visible 
aggregation occurred; suggesting surface PEG strands were effective for repelling other 
particles. Despite no visible aggregation, particle sizing data of PEGylated nanoparticles 
(Fig 3.17C), after incubation with 1 mg and 1.5 mg doxHCl, showed increased particle 
size. This may be explained by transient particle-particle interactions where PEG strands 
momentarily intertwined and then came apart or where nanoparticle surfaces without 
PEG coverage interact to form transient complexes. Overall, particle size still remained 
below 350 nm, which was in line with or below many previously reported particle 
diameters. 
3.4.4.5.4 Drug loading 
 
 DoxHCl extraction from solution, again, decreased with increasing drug in the 
incubation media while drug loading increased due to higher doxHCl concentration 
gradient (Fig. 3.17A). Extraction efficiency of PEGylated nanoparticles was slightly 
below that for regular nanoparticles, and with 1.5 mg doxHCl in the incubation media, 
extraction efficiency by PEGylated nanoparticles was still as high as 65%. The slightly 
lower extraction efficiency may be attributed to the outer shell of PEG strands that may 
repel a small percentage of doxHCl molecules in solution and slow their migration into 
the nanoparticle. Despite the substitution of PEG-PLA for a portion of resomer 502H, 
which reduced the number of carboxylic acids available for drug binding, drug loading 
values for regular and PEGylated nanoparticles were similar across the different 
drug:nanoparticle ratios. In fact, by preventing aggregation, PEGylated nanoparticles 
with maximal KTpClPB loading achieved up to 6% drug loading (Fig. 3.17B), which was 
much higher than most published drug loading values.  
3.4.5. Vinblastine sulfate uptake 
 
 Vinblastine sulfate (VS), like doxorubicin hydrochloride, was commonly used for 
cancer treatment. As a small molecule drug, it has a molecular weight of 810.97 daltons 
with a number of fused rings in its structure (Fig. 3.19) that could be beneficial for 
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hydrophobic interactions, much like doxHCl. In terms of physicochemical properties, VS 
has moderate solubility in aqueous medium (greater than 10 mg/mL) and a reported pKa 
of 7.4 (Gaertner, Murray et al. 1998), which meant that under physiological conditions, 
around 50% of VS molecules should have a net positive charge. Because its intrinsic 
properties matched the type of drug whose loading we would like to improve using the 
specially formulated KTpClPB-loaded PEGylated nanoparticles, vinblastine sulfate was 
used as an additional model drug to demonstrate the potential utility of these 
nanoparticles toward this category of drug. 
 Several formulations were studied using either KTpClPB-free or KTpClPB-
loaded PEGylated nanoparticles to further demonstrate improvements due to KTpClPB. 
PEGylated nanoparticles were loaded with vinblastine sulfate at either room temperature 
or 37
o
C to see if the temperature-induced drug loading increase seen before also applied. 
KTpClPB-loaded PEGylated nanoparticles with no VS loaded was used as a control.
 Results showed that as drug loading temperature increased from room 
temperature to 37
o
C, actual drug loading improved from 3.77% to 5.98% while 
encapsulation efficiency improved from 22.6% to 35.9% (Table 3.6). This improvement 
again showed that the temperature effect on drug loading was dependent on the 
nanoparticles or polymer used and this system was effective for both doxHCl and VS. 
With KTpClPB incorporation into the nanoparticles, drug loading increased from 5.98% 
to 8.98% and encapsulation efficiency improved from 35.9% to 53.9% (Table 3.6). This 
was significant as almost half of the drug initially present in the incubation medium was 
taken up by the nanoparticles and further showed that KTpClPB presence significantly 
enhanced drug loading. It was also interesting to see that vinblastine sulfate loading into 
these nanoparticles was higher than for doxHCl and this could be due to the additional 
fused rings in its structure that provide improved stability in the hydrophobic core of 
nanoparticles. Alternatively, this loading difference relative to doxHCl may be due to the 
higher molecular weight of VS. 
 The above results with VS provided evidence that drug loading improvements 
using KTpClPB-loaded PEGylated nanoparticles were not exclusive to doxorubicin 
hydrochloride and it would be interesting to know if these particles and drug loading 
systems could be applied to other drugs.  
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3.4.6 Charge quantification calculations 
 
 Previous studies demonstrated significant increases in doxHCl and VS drug 
loading when the polymer, 502H, and KTpClPB were used to formulate the ion 
complexing nanoparticles. Assuming that all available charges of 502H polymer and 
KTpClPB could be used for ion pairing with drug molecules on a charge-for-charge basis, 
it would be interesting to calculate the theoretical drug loading in these nanoparticles. 
 First, the effect of 502H polymers on doxHCl loading was calculated. 502H 
polymers have an acid number of minimum 6 mg KOH/gram polymer according to the 
company (Boehringer Ingelheim) website. This meant that since KOH has a molecular 
weight of 56.1 g/mol, approximately 17.82 µmol of KOH may be neutralized by protons 
contributed by carboxylic acids in one grams of this polymer, which was also the same as 
saying that 17.82 µmol of doxorubicin could be neutralized by one gram of this polymer. 
Because 80 mg of 502H was used to make each batch of nanoparticles, this meant 1.426 
µmol or 0.827 mg (doxHCl MW: 580 g/mol) of doxorubicin could be loaded into these 
nanoparticles by ion pairing. Finally, 0.827 mg of doxHCl in 80 mg of 502H 
nanoparticles would be equivalent to 1.02% drug loading. This theoretical drug loading 
was lower than the actual loadings observed in the temperature-dependent drug uptake 
study (Fig. 3.12A), where drug loadings in KTpClPB-free 502H nanoparticles were 1.4% 
and 3%, at room temperature and 37
o
C, respectively. The increase in the actual drug 
loading could be due to hydrolysis of 502H during nanoparticle formulation which 
generated additional free acids in the polymer; although a more likely explanation was 
that the acid number reported by the manufacturer was only a minimum, and the actual 
acid number, was approximately 11.5 (determined by standard titration with potassium 
hydroxide by Dr. Ying Zhang), or twice the reported value. This meant the theoretical 
drug loading should have been 2.04%, which was closer to the actual values of 1.4% and 
3%. 
 Because only 2 mL of ethyl acetate was used during nanoparticle formulation and 
KTpClPB had a solubility of 2.4 mg/mL in ethyl acetate, the maximal amount of 
KTpClPB that was theoretically added into each batch of nanoparticles was 4.8 mg. Since 
a previous KTpClPB extraction study found that encapsulation efficiency of KTpClPB in 
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nanoparticles was around 40% (Table 3.2), this meant that 1.92 mg of KTpClPB was 
actually encapsulated into each batch of nanoparticles. Assuming that each molecule of 
KTpClPB could ion pair with a molecule of doxHCl and that molecular weights of 
KTpClPB and doxHCl are 496 g/mol and 580 g/mol, respectively, this meant 1.92 mg of 
KTpClPB can bind to 2.25 mg of doxHCl. If 80 mg of 502H was used to formulate 
nanoparticles, this would have been equivalent to 2.67% increase in drug loading due to 
KTpClPB. Looking at actual result, there was an increase in drug loading from 3% to 
4.8% between KTpClPB-free nanoparticles and nanoparticles with maximal KTpClPB 
incorporation (Fig 3.12A), which meant that presence of KTpClPB led to 1.8% increase 
in loading. Comparing the actual increase of 1.8% and theoretical increase of 2.67%, this 
meant that 2/3 of available KTpClPB were ion paired, which was substantial.   
 Lastly, it was observed that vinblastine sulfate loading into KTpClPB-free 
nanoparticles were 3.77% and 5.98% at room temperature and 37
o
C, respectively (Table 
3.6). Since 80 mg of 502H were used to make each batch of nanoparticles, based on 
reported acid number for 502H, this meant 1.426 µmol or 1.16 mg (vinblastine MW: 811 
g/mol) of vinblastine could be loaded into these nanoparticles by ion pairing. 1.16 mg of 
vinblastine in 80 mg of 502H would have been equivalent to 1.43% theoretical drug 
loading (charge basis). However, since the measured acid number was almost twice the 
reported value, this meant the theoretical drug loading should have been almost 2.9%. 
This theoretical drug loading almost matched drug loading at room temperature, 3.77%, 
although it still fell short of the 5.98% achieved at 37
o
C. One potential reason for the 
significantly higher drug loading relative to the theoretical value may be due to the 
structure of vinblastine, which contained more alkyl rings that may promote compatibility 
with the hydrophobic core of nanoparticles. In addition, if we again assume that 1.92 mg 
of KTpClPB was actually encapsulated into each batch of nanoparticles and that 
KTpClPB and vinblastine sulfate have molecular weights of 496 g/mol and 811 g/mol, 
respectively, this meant 1.92 mg of KTpClPB could bind 3.14 mg of vinblastine sulfate. 
Since 80 mg of 502H was used to formulate these nanoparticles, this meant the presence 
of KTpClPB led to an increase in theoretical loading of 3.7%. Because drug loading 
actually increased from 5.98% to 8.98% with incorporation of maximal amount of 
KTpClPB (Table 3.6), the 3% actual increase in drug loading was close to the theoretical 
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improvement of 3.7% and indicated that approximately 80% of available KTpClPB was 
bound to vinblastine molecules. 
3.4.7 Plasma drug uptake study 
 
 Previous in vitro results demonstrated PEGylated nanoparticles in this study could 
effectively take up the model drugs, doxorubicin hydrochloride and vinblastine sulfate, 
after optimization. Ultimately, it was hoped that the successful in vitro results could 
translate into equivalent in vivo data; however, before conducting lengthy and difficult in 
vivo studies, a proof of concept should be done under simulated physiological conditions, 
or in plasma, which to the best of our knowledge, has not been done before. In this study, 
plasma suspensions containing different concentrations of dissolved doxHCl (from a 
normal therapeutic dose up to four times the therapeutic dose) were incubated with or 
without blank PEGylated nanoparticles and free drug concentration after incubation were 
determined. 
 To choose the proper conditions for this study, two things had to be calculated. 
One was an appropriate nanoparticle concentration in plasma, while the other was the 
normal therapeutic concentration of doxHCl in plasma (assuming 70% plasma protein 
drug binding). Doxil
®
, a nanoparticulate liposome containing doxHCl, was widely used 
clinically for cancer treatment, so its nanoparticle concentration per dose was used for 
this study. Normally, around 1 gram of liposomes was administered per dose and since an 
average person has around 3 liters of plasma, this calculated to a dose of 1 mg 
nanoparticle / 3 mL of plasma (1 mg/3 mL). For doxHCl dose calculation, the normal 
dose of Adriamycin
®
, i.e., 150 mg (60-75 mg/m
2
 while an average 6 feet human was 
around 2 m
2
) was used. Because the human body has around 3 liters of plasma, this 
translated to 50 µg/mL of total doxHCl concentration in plasma. Since doxHCl binding 
by plasma protein was 70%, free doxHCl concentration in plasma was 15 µg/mL. In 
addition to these two theoretical drug concentrations, a concentration in between these 
(30 µg/mL) as well as potentially toxic doses of 2X, 3X, and 4X the normal therapeutic 
concentration of 50 µg/mL were tested. 
 Plasma doxHCl concentrations, after drug extraction in the presence or absence of 
PEGylated nanoparticles, were measured while initial drug concentrations were used to 
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denote each formulation. Final free doxHCl concentrations, without addition of 
nanoparticles, were smaller than the theoretical drug concentrations due to plasma protein 
drug binding. Calculations showed that drug binding was consistently around 60% (not 
shown) while reported human plasma protein doxHCl binding was around 70% although 
values of between 50% and 70% have also been observed.  
For the tested doxHCl concentrations near its normal therapeutic concentration 
(15 – 50 µg/mL) (Table 3.7), the effect of nanoparticles were relatively insignificant as 
the percent drug concentration reduction was between 7.7%-9.44%, which only translated 
to actual reduction of between 0.5-1.8 µg/mL. Nanoparticle drug loading here was only 
between 0.18-0.6%, which was insignificant considering these PEGylated could have a 
theoretical drug loading of up to 6 - 7%. Between 100 and 150 µg/mL (2X or 3X the 
normal dose of 50 µg/mL), the percent drug concentration reduction was 6.96% and 8.4%, 
respectively, which was comparable to those at normal drug dose, but drug loading 
improved slightly to 0.9% and 1.66%, showing that more drug molecules were starting to 
diffuse into the nanoparticles. At 200 µg/mL initial doxHCl concentration, absolute drug 
concentration reduction suddenly jumped to more than 13 µg/mL, or 15.71%. More 
importantly, drug loading of the nanoparticles increased to 4.35%, an almost 3-fold 
increase compared with the study done at 150 µg/mL.  
The above results were surprising considering previous in vitro studies showed an 
active and quick uptake of doxHCl molecules by the PEGylated nanoparticles that was 
limited only by the maximal drug loading potential. However, these differences could be 
explained by the presence of dissolved plasma proteins, which were not present during 
the in vitro studies. These proteins have a tendency to reversibly adsorb to hydrophobic 
nanoparticle surface despite the presence of hydrophilic PEG polymers on the 
nanoparticles, which was only around 2.5% by total nanoparticle weight and was not 
effective for shielding the entire nanoparticle surface from the plasma proteins. Thus, any 
drug molecules that came into contact with nanoparticles was likely to first encounter an 
outer shell of plasma proteins and was preferentially bound by these proteins until 
gradually, available protein binding sites were saturated and excess drug could access and 
bind to nanoparticle itself.  
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 Both percent plasma drug concentration reduction and drug loading results also 
suggested the PEGylated nanoparticles were not effective around the normal therapeutic 
concentration of 50 µg/mL, which was actually desirable considering a minimum 
therapeutic concentration was needed for treatment. At 4X the normal therapeutic 
concentration and above, the PEGylated nanoparticle could be very effective for treating 
potential drug overdose considering the high drug loading and quick uptake (30 minute 
incubation time). Although not tested here, drug loading results indicated that more drug 
uptake into the nanoparticles were possible considering these particles could reach up to 
6% drug loading. Although only doxHCl was tested in this study, these nanoparticles 
could be effective for the broad category of small molecule drugs, including vinblastine 
sulfate, to reduce potential toxicity. 
3.5 Conclusions 
 
 Anionic borates demonstrated great potential as model lipophilic anions with 
successful extraction of a model hydrophilic drug, doxorubicin hydrochloride (doxHCl), 
from aqueous to the organic phase via ion pairing. Of the borates studied, KTpClPB was 
most suitable for nanoparticle incorporation and was incorporated into regular or 
PEGylated nanoparticles at high concentrations to form spherical nanoparticles with PEG 
localized on the outer shell according to XPS. 
 In vitro incubation drug loading procedure, tested with these specially formulated 
nanoparticles, successfully extracted two model drugs, doxorubicin hydrochloride and 
vinblastine sulfate, into the particles at high concentrations. This drug loading process 
was optimized using polymers with high acid number (more negative charges for ion 
complexing), maximizing the KTpClPB loading into nanoparticles, increasing incubation 
temperature, maximizing drug:nanoparticle (wt/wt) ratio, and using PEGylated 
nanoparticles. These improvements enhanced loading by potentially increasing the 
density of available negative charges in nanoparticles for ion pairing, introducing 
potential hydrophobic interaction between drug and KTpClPB molecules to stabilize and 




 Plasma doxHCl uptake, using optimized PEGylated nanoparticles, was negligible 
when the normal therapeutic dose of doxHCl was administered, which was desirable. 
However, such particles effectively reduced both plasma drug concentration and achieved 
high drug loading when 4X the normal therapeutic concentration was administered. This 
promising result suggested potential application of these nanoparticles as treatment for 
drug overdose of small molecule drugs with similar properties to doxHCl. 
Overall, the combination of KTpClPB-loaded PEGylated nanoparticles and an 
optimized absorption/extraction loading process could significantly enhance active drug 
loading and provide a viable alternative to entrapment and conjugation-based drug 































Table 3. 1. Properties of the borate compounds studied 





C16H12BS4K 382.44 6.152 
Sodium tetraphenyl borate 
(NaTPB) 
C24H20BNa 342.23 7.568 
Potassium tetrakis(4-
chlorophenyl)borate (KTpClPB) 




C32H12BF24K 902.32 14.632 
#










































7:1-502H/PEG-PLA None None 0 0 
7:1-502H/PEG-PLA 10.7 None 4.19 ± 0.04 39.12 
7:1-502H/PEG-PLA 10.7 
1 hour in 
DIW 
4.02 ± 0.1 37.54 
7:1-502H/PEG-PLA 10.7 
30 min in 
PBS 










































Viscosity Acid number 
Resomer® RG 502H ~15,000 0.2 dl/g min. 6 mg KOH/g 
Resomer® RG 503H ~38,000 0.34 dl/g min. 3 mg KOH/g 
Resomer® RG 503 ~45,000 0.42 dl/g 










































Table 3. 4. Atomic % composition of C1s, O1s, and N1s; of XPS C1s core-level spectra of 
various nanoparticle samples 
Atomic composition (%) 
Nanoparticle samples 
C1s O1s N1s 
PLGA 43.6 56.4 0.0 
PEG-PLA 48.6 51.4 0.0 
PLGA:PEG-PLA 45.8 54.2 0.0 
PLGA + KTpClPB 45.4 54.6 0.1 
PLGA:PEG-PLA + 
KTpClPB 
51.2 48.8 0.0 
PLGA:PEG-PLA + 
KTpClPB + doxorubicin 
































Table 3. 5. Decomposition of C1s peak (% envelope ratios) of nanoparticle samples 















PLGA 26.91 10.35 28.69 33.04 
PEG-PLA 30.62 18.04 25.63 25.70 
PLGA:PEG-PLA 27.79 11.15 29.58 31.49 
PLGA + KTpClPB 29.50 11.02 27.38 32.09 
PLGA:PEG-PLA + 
KTpClPB 

































Table 3. 6. Drug loading and encapsulation efficiency for vinblastine sulfate 
Nanoparticle formulation Drug loading (%) E.E. (%)
*
 
502H:PEG(7:1)-room temp 3.77 ± 0.54 22.6 
502H:PEG(7:1)-37
o
C 5.98 ± 0.90 35.9 
502H:PEG(7:1)-KTpClPB 8.98 ± 0.76 53.9 
*



























Amt dox added/3.1 











15 µg/mL 45 7.01 ± 0.31 6.47 ± 0.16 7.70 0.18 
30 µg/mL 90 12.21 ± 0.59 11.21 ± 0.40 8.19 0.33 
50 µg/mL 150 19.38 ± 0.40 17.55 ± 0.71 9.44 0.60 
100 µg/mL 310 39.82 ± 1.93 37.05 ± 0.56 6.96 0.90 
150 µg/mL 470 60.71 ± 2.28 55.61 ± 1.33 8.40 1.66 
200 µg/mL 620 84.85 ± 3.17 71.52 ± 2.06 15.71 4.35 
*
 Formulations denoted by theoretical doxHCl concentrations originally present in plasma 
#










































































Figure 3. 2. Structures of the borate compounds studied, (A) sodium tetraphenylborate 
(NaTPB), (B) potassium tetrakis(2-thienyl)borate (KTTB), (C) potassium tetrakis(4-













































































































































Figure 3. 4. Doxorubicin hydrochloride extraction into blank ethyl acetate at different 
aqueous doxHCl concentrations (A) or at 1:0.5, 1:1, and 1:1.5 molar ratios (left to right, 















































Figure 3. 5. Percent doxHCl extraction into ethyl acetate phase with and without 








































































5,000 25,000 19,408.54 22,689.8 
1. Calculated based on wt ratios of PEG and L-lactide added during PEG-PLA synthesis 
2. Calculated based on area ratios of peaks A and B 
3. Caclulated based on area ratios of peaks A and C 
 
 
Figure 3. 6. (A) 
1
H-NMR spectrum of methoxyPEG-PLA copolymer in deuterated 
chloroform and (B) associated table with theoretical and calculated molecular weights of 








































4 mL 3% PVA 
probe sonicate for 20 sec to 
form O/W emulsion 
stir 4-5 hrs 
end product: O/W nanoparticles 
Oil Phase: 2 mL ethyl acetate 
with polymer and KTpClPB 
wash with stir cell 















Figure 3. 8. SEM images of KTpClPB-loaded O/W nanoparticles at different 

































































































Res502H-EA -30.3 -14.7 179.5 0.155 
Res503H-EA -25.5 -14.5 189.8 0.133 
Res503H-MC -33.7 -23.1 229.4 0.108 
Res503-MC -36.2 -18.9 240.2 0.159 
 
Figure 3. 10. DoxHCl extraction/absorption into nanoparticles made with different 
polymers with extraction efficiency and drug loading (A) and associated table of zeta 





















































































































0.00 0 -30.4 -21.3 182.5 
1.48 1.2 -33.8 -18 161.7 
2.91 2.4 -37.2 -15.7 142.6 
5.66 4.8 -35.4 -17.3 117.1 
 
Figure 3. 11. DoxHCl extraction/absorption into nanoparticles made with different 
polymers with extraction efficiency and drug loading (A) and associated table of zeta 
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Zeta potential after 
extraction (mV) 



















0.00 -30.4 -21.3 -22.3 178.4 182.5 
1.48 -33.8 -18.0 -18.9 166.1 161.7 
2.91 -37.2 -15.7 -20.9 145.1 142.6 
5.66 -35.4 -17.3 -22.2 128.0 117.1 
 
Figure 3. 12. DoxHCl extraction/absorption into KTpClPB-loaded 502H nanoparticles at 
different temperatures with extraction efficiency and drug loading (A) and associated 
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0.25 -35.4 -24.5 120.2 
0.5 -35.4 -26.6 123.0 
1 -35.4 -22.1 117.1 
 
Figure 3. 13. DoxHCl extraction/absorption into KTpClPB-loaded 502H nanoparticles at 
different amounts of doxHCl to 15 mg nanoparticles with extraction efficiency and drug 
loading (A) and associated table of zeta potential and size of drug-loaded nanoparticles at 
































































Figure 3. 15. General XPS survey scans of PEGylated nanoparticles with characteristic 








































Figure 3. 16. Synthetic XPS peak fits for C1s envelopes of PLGA (A), PEG-PLA (B), 
PLGA:PEG-PLA (7:1, wt/wt) (C), PLGA + KTpClPB (D), PLGA:PEG-PLA + KTpClPB 












































































































































































0 (blank) -35.4 -35.7 132.0 128.8 
0.25 -24.5 -38.7 120.2 115.0 
0.5 -26.6 -33.5 123.0 112.8 
1 -22.1 -24.0 117.1 230.1 
1.5 NA* -26.4 NA* 322.1 
*
Aggregation of non-PEGylated nanoparticles 
 
Figure 3. 17. DoxHCl extraction/absorption into regular or PEGylated nanoparticles at 
different ratios of doxHCl to 15 mg nanoparticles with extraction efficiency (A) and drug 
loading (B) and associated table of zeta potential and size of drug-loaded regular or 
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Figure 3. 18. SEM of non-PEGylated (top row) and PEGylated (bottom row) 
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Comparison of Reverse Loading with Common Emulsion-Based Loading Methods 




 Traditional delivery of doxorubicin hydrochloride (doxHCl) by emulsion-based 
polymeric nanoparticles, where drug is entrapped into nanoparticles during its formation, 
have suffered from low drug loading and poor encapsulation efficiency as well as burst 
release. During this study, doxHCl was loaded with a novel reverse drug loading 
procedure, where drug was loaded into pre-formulated blank nanoparticles, and compared 
with traditional emulsion nanoparticles (water-in-oil-in-water (W/O/W) and oil-in-water 
(O/W)). A lipophilic borate-based anion, KTpClPB, was incorporated into the 
nanoparticles for optimized reverse drug loading and drug incorporation. Results showed 
traditional entrapment methods (W/O/W and O/W) were improved by incorporation of 
the lipophilic anion KTpClPB into polymeric nanoparticles, with drug loading increasing 
from 1.3% up to 3.3%. Comparatively, reverse drug loading, after optimization and using 
KTpClPB-loaded polymeric nanoparticles, reached doxHCl loading of up to 7% using a 
simple process. Release from reverse drug loaded nanoparticles showed an initial 30% 
drug release within 3 hours with close to 80% drug released in 2 days, however, there 
were no significant differences in drug release profiles between traditional or reverse 
loaded nanoparticles and presence of KTpClPB did not appear to improve drug release. 
Overall, the results showed the reverse loading strategy was superior to traditional drug 
loading strategies for drug delivery. 
4.2 Introduction 
 
Over the past several decades, interest in using biodegradable polymeric 
nanoparticles as drug delivery vehicles have intensified due to advantages such as small 
 131 
 
size, ability to load and preserve the efficacy of different drugs, passive and active 
targeting and formulation using different polymers to confer different properties. In terms 
of size range, polymeric nanoparticles have diameters between 10 to 1000 nm, allowing 
them to freely circulate in the bloodstream without causing blockage (Yang, Wang et al. 
2006). Different types of drugs may also be encapsulated into nanoparticles through 
entrapment, chemical conjugation, or adsorption methods; which can protect drugs 
against degradation, promote controlled and sustained drug release, and reduce side 
effects (Soppimath, Aminabhavi et al. 2001; Sahoo and Labhasetwar 2003). In addition, 
nanoparticles can improve drug accumulation at disease sites via passive or active 
targeting. Passive targeting takes advantage of a phenomenon called enhanced 
permeability and retention (EPR) effect, where nanoparticles accumulate in solid tumor 
regions with a more leaky and permeable vasculature and impaired lymphatic drainage. 
Active targeting can be achieved by conjugating ligands, such as antibodies, peptides, 
and sugars, which target antigens overexpressed on disease cells of interest, to the surface 
of nanoparticles (deVerdiere, Dubernet et al. 1997; Maeda, Wu et al. 2000; Abou-Jawde, 
Choueiri et al. 2003; Yang, Wang et al. 2006). Moreover, numerous polymers have been 
synthesized to study improved nanoparticle production and design, with the polyester 
family, including members such as poly(lactic acid) (PLA), poly(ε-caprolactone) (PCL), 
and poly(lactide-co-glycolide) (PLGA), receiving attention because of their 
biocompatibility and biodegradability (Astete and Sabliov 2006); PLGA, in particular, 
has been used in numerous FDA-approved medical devices. 
One drug that has benefited from polymeric nanoparticle delivery is doxorubicin 
hydrochloride (doxHCl) (Fig. 4.1). This chemotherapeutic drug is effective against a 
range of tumor cells and kills cells by intercalating between DNA helix to prevent cell 
replication. It is made of hydrophobic fused rings covalently linked to a hydrophilic sugar 
moiety with an attached amine group with a pKa of 8.2. Despite their effectiveness, 
doxHCl has many side effects, including life-threatening cardiotoxicity, due to poor 
targeting ability and short plasma half-life.  
DoxHCl efficacy has been improved using polymeric nanoparticles formulated 
through traditional emulsion-based methods where drug can be dissolved in the aqueous 
phase or first extracted into an organic phase to facilitate drug entrapment during 
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nanoparticle formation; although new problems that have arisen include low drug loading, 
low encapsulation efficiency and initial burst release (Soppimath, Aminabhavi et al. 2001; 
Galindo-Rodriguez, Allemann et al. 2004). Examples of these different emulsion 
formulations include oil-in-water (O/W) emulsion, where doxHCl is converted into 
hydrophobic doxorubicin and dissolved in the oil phase along with a polymer and 
emulsified to form nanoparticles, and water-in-oil-in-water (W/O/W) emulsion, where 
doxHCl is dissolved in an inner aqueous phase and emulsified into polymer-containing 
oil phase, and then this primary emulsion is again emulsified into an outer aqueous phase 
to form nanoparticles.  
In recent years, another loading strategy, adsorption drug loading, where blank 
nanoparticles are incubated in a concentrated drug solution to facilitate drug uptake, has 
been applied more frequently and has proven to be effective for loading different drugs at 
relatively high loading (Asuri, Karajanagi et al. 2007; Arias, Linares-Molinero et al. 
2008). More recently, this strategy has been combined with another technique, ion 
complexation, which takes advantage of electrostatic interactions between drug 
molecules and opposite charges embedded in nanoparticles to increase drug loading and 
encapsulation efficiency to further enhance drug uptake. Together, this created an active 
uptake mechanism that can “sucks” up drugs it comes into contact with, instead of solely 
relying on passive drug concentration gradient for drug to diffuse into nanoparticles. For 
this reason, this uptake procedure will be referred to as “reverse drug loading” during this 
study.  
Various studies have demonstrated benefits of ion complexing nanoparticles for 
improved drug loading, encapsulation efficiency, release profile, and pharmacokinetic 
drug distribution (Janes, Fresneau et al. 2001; Cavalli, Gasco et al. 2002; Wong, 
Bendayan et al. 2004; Wong, Rauth et al. 2006; Cafaggi, Russo et al. 2007; Chavanpatil, 
Khdair et al. 2007; Tian, Bromberg et al. 2007). Currently, this strategy has been mainly 
used with anionic polymers or copolymers specially synthesized for uptake of 
protein/peptides due to their potential degradation under normal drug loading conditions. 
Examples of  this include using sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-
glycolide) to incorporate tetanus toxoid (Jung, Breitenbach et al. 2000), poly(ε-
caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) to enhance human basic 
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fibroblast growth factor incorporation and using poly(styrene-co-4-styrene-sulfonate) to 
enhance lysozyme loading (Cai, Bakowsky et al. 2008). 
With all the potential advantages of ion complexing nanoparticles and reverse 
drug loading, this system will be applied to doxHCl to promote its loading relative to 
existing emulsion-based method. This study was designed as follows. First, a model 
lipophilic anion, KTpClPB, will be tested for its potential to be loaded into polymeric 
nanoparticles using O/W or W/O/W emulsion procedures. Then, various properties, such 
as drug loading, particle size, and in vitro release, will be compared for traditional O/W 
and W/O/W nanoparticles with entrapped doxHCl and ion-pairing nanoparticles with 
doxHCl taken up via reverse loading. Lastly, optimization of reverse loading procedure 




Potassium tetrakis(4-chlorophenyl)borate (KTpClPB) was purchased from Sigma-
Aldrich. Doxorubicin hydrochloride (doxHCl) (>99% purity, lyophilized powder) was 
purchased from Hisun Pharmaceuticals (China) and vinblastine sulfate (>99% purity) was 
generously donated by Hisun Pharmaceuticals (China). Poly(D,L-lactide-co-glycolide), 
50/50, with inherent viscosity of 0.2 dL/g and MWw of 15 kDa (resomer 502H) and 0.34 
dL/g and MWw of 38 kDa (resomer 503H), were purchased from Boehringer Ingelheim. 
Poly(vinyl alcohol) (PVA) of MWw of 25,000 (88% hydrolyzed) was purchased from 
Polysciences Inc. L-lactide (>99% purity) was purchased from Sigma-Aldrich. Methoxy-
poly(ethylene glycol) (mPEG-NH2, MWw = 5,000) was purchased from Nektar 
Therapeutics. Spectra/por 7 dialysis bags (MWCO: 10-12K or 50K, Spectrum) were 
purchased from Fisher Scientific. All other chemicals and solvents were of analytical 
grade and purchased from commercial suppliers.  





4.3.2 PEG-PLA copolymer synthesis 
 
The methoxy-poly(ethylene glycol)-poly(lactic acid) (PEG-PLA) was synthesized 
by a standard ring opening polymerization. Briefly, L-lactide (Sigma, 98% purity) was 
pre-purified by recrystallization from ethyl acetate and the catalyst, stannous octoate 
(Tin(II) 2-ethylhexanoate, Sigma, 95% purity), was pre-purified by distillation. The 
desired molar ratio of L-lactide to mPEG-NH2 was weighed out and added to the reaction 
flask followed by addition of stannous octoate at equivalent molar ratio to mPEG-NH2. 
Dry toluene (10 mL / 1.5 g of reactants) was added to dissolve and mix the reagents. The 
reaction proceeded with stirring at 110
o
C for 2 hours under moisture-free argon 
atmosphere. At the end of the polymerization step, copolymer was purified and recovered 
as follows. The copolymer crystallized upon cooling and was dissolved with cooled 
dichloromethane followed by ether addition to reprecipitate the copolymer. The previous 
procedure was repeated and the copolymer was collected by filtration on a Buchner 
funnel. They were then dried at 37
o
C in a vacuum oven overnight.  
PEG-PLA was analyzed by 
1
H NMR spectroscopy using a Bruker DRX 500 
spectrometer (Bruker Biospin Inc., Billerica, MA) operating at 500 MHz. Peak areas for 
different hydrogens were used for PEG-PLA molecular weight determination. 
4.3.3. General nanoparticle preparation 
 
Nanoparticles were formulated using either oil-in-water (O/W) or water-in-oil-in-
water (W/O/W) emulsion procedure (Fig. 4.2). For O/W emulsion, different amounts of 
polymer were dissolved in 2 mL ethyl acetate (oil phase) and emulsified, by sonication 
(20 seconds) on ice using a probe sonicator (Sonics VibraCell) at 50% power, in 2 mL 
3% PVA solution (aqueous phase). The O/W emulsion was diluted into 40 mL of 0.075% 
PVA solution under rapid magnetic stirring for 4-5 hours. Nanoparticle suspensions were 
collected and washed using an Amicon Stirred Cell with a 50 nm Millipore Nitrocellulose 
filter. W/O/W emulsion formulation was similar to O/W except that 0.3 mL of DIW 
(inner aqueous phase) was first emulsified, by sonication (30 seconds) on ice using a 
probe sonicator (Sonics VibraCell) at 50% power, in 2 mL ethyl acetate (oil phase) 
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containing dissolved polymer. This primary emulsion was further emulsified in 2.4 mL of 
3% PVA solution (outer aqueous phase). 
KTpClPB-loaded nanoparticles were formulated using the same O/W or W/O/W 
procedure above except that predetermined amounts of KTpClPB were dissolved in ethyl 
acetate before emulsification. 
For doxHCl loading into O/W nanoparticles during formulation (emulsion 
procedures), the process remained the same except that ethyl acetate with known 
KTpClPB concentration was used to extract doxHCl from aqueous to the ethyl acetate 
phase and then used as the oil phase. DoxHCl concentration in the aqueous phase before 
and after extraction was determined using HPLC protocol (see below) to determine the 
amount of doxHCl in the ethyl acetate (oil) phase. For drug loading into W/O/W 
nanoparticles, all steps remained the same except that 2.5 mg doxHCl was first dissolved 
in the inner aqueous phase. 
PEGylated nanoparticles were formulated using the same O/W procedure above 
with modifications. 502H PLGA and KTpClPB were dissolved in 2 mL ethyl acetate and 
mixed with PEG-PLA dissolved in 0.2 mL methylene chloride. This oil phase was 
emulsified in 2.2 mL of 3% PVA solution. All other steps were unchanged. 
4.3.4 DoxHCl concentration determination methods 
4.3.4.1 HPLC method 
 
A Waters HPLC system (Waters, Milford, MA) was used for chromatographic 
separation of doxHCl. It consisted of a 1525 Binary HPLC pump, 717 plus autosampler, 
and 474 scanning fluorescence detector. Waters Breeze
®
 chromatography software was 
used to acquire and process data. A Waters Nova-Pak
®
 C18 column (3.9 x 150 mm I.D.) 
(Waters, Milford, MA) was used with a filtered and degassed ACN : 20 mM, pH 3 
potassium phosphate : TFA (30:70:0.1, v/v/v) mobile phase. Chromatography was 
performed at a flow rate of 1 mL/min and fluorescence detection was set at λexcitation of 
480 nm and λemission of 590 nm at room temperature. 




4.3.4.2 UV method 
 
A Beckman DU650 spectrophotometer was used for UV analysis. Samples or 
standards containing doxHCl in methanol were analyzed using a quartz 
spectrophotometer cell (Starna Cells Inc.) at a scanning rate of 1200/min and scanning 
range of 400-750 nm. Absorbance wavelength was set at 480 nm and all sample had 
baseline reading set at 750 nm.  
4.3.5 Nanoparticle physical characterization 
4.3.5.1 Particle size/zeta potential determination 
 
Nanoparticle suspensions were diluted to 0.5 mg/mL and transferred into fold 
capillary cells for both zeta potential and particle size determination. Samples were 
analyzed using a Malvern ZetaSizer Nano ZS (Malvern Instruments). 
4.3.5.2 SEM morphological analysis 
 
Nanoparticle suspensions were diluted to 50 µg/mL and dried overnight on 
viewing stubs. Morphology was observed, after coating with a layer of gold (2-5 nm), by 
scanning electron microscopy (Philips XL30 Field Emission Gun Scanning Electron 
Microscopy). 
4.3.6 Reverse drug loading procedure  
 
Drug was dissolved to desired concentrations in deionized water (DIW). Both the 
drug solution and a blank nanoparticle suspension (with known concentration) were 
added consecutively into DIW so that 1) drug and nanoparticle reach desired 
concentrations and relative weight ratio and 2) final suspension volume reached 4 mL. 
Mixtures were shaken (Ika KS130 instrument) for 1 hour at different temperatures.  
 After drug loading, mixtures were dialyzed in spectra/por 7 dialysis bag (MWCO: 
50K, Spectrum) against 1 liter of DIW (replaced every hour during the first 3 hours) over 
 137 
 
24 hours. Dialyzed suspensions were used for size, zeta potential, and drug loading 
determination. 
4.3.7 Drug loading determination 
 
Drug-loaded nanoparticle suspensions were lyophilized (in triplicate) and 
weighed into 2 mL polypropylene tubes. 0.1 mL methylene chloride was added to 
nanoparticles, followed by shaking for 10 minutes, then addition of 1.5 mL methanol and 
shaking for over 12 hours. These suspensions were spun down at 13,200 RPM for 8 min. 
Supernatant containing dissolved drug was diluted using methanol. Drug concentration 
was analyzed using UV doxHCl concentration determination procedure above. 
4.3.8 In vitro drug release 
 
Known amounts of drug-loaded nanoparticles or free doxorubicin hydrochloride 
were suspended or dissolved in 0.4 mL phosphate buffered saline (PBS) in a dialysis bag 
(spectra/por 7, MWCO: 50K). The dialysis bag was incubated in 15 mL PBS and shaken 
(Ika KS130) at 37
o
C. Release media was collected and completely replaced at pre-
determined time intervals with fresh incubation media. Drug concentration in the release 
media was analyzed using HPLC analysis procedure above.  
4.4 Results/Discussion 
4.4.1 Traditional nanoparticle formulation strategies 
 
 Drug loading, an essential property of nanoparticles, may be important for 
reducing total administered dose of a drug and administration time per dose as well as 
indirectly improving drug targeting and reduce side effects. For polymeric nanoparticles, 
a common formulation/drug loading strategy was emulsification/solvent evaporation, 
where drugs were encapsulated or entrapped during nanoparticle formation. Two of the 
most commonly utilized versions of this strategy include water-in-oil-in-water (W/O/W) 
and oil-in-water (O/W) emulsions (Verrecchia, Huve et al. 1993; Sjostrom, Kaplun et al. 
1995; Zambaux, Bonneaux et al. 1998). Despite their effectiveness, improvements in 
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drug loading and encapsulation efficiency for hydrophilic small molecule drugs such as 
doxorubicin hydrochloride (doxHCl) may be possible. Here, ion pairing strategy, with 
incorporation of a model lipophilic anion, KTpClPB, was combined with emulsion 
formulation to test for improvements in drug loading and encapsulation efficiency of a 
model drug, doxorubicin hydrochloride (doxHCl). 
 Traditional W/O/W and O/W emulsion, with doxHCl and KTpClPB incorporation 
during nanoparticle formation, were formulated using a procedure outlined in Fig. 4.3. 
An earlier study (Chapter 3, Table 3.2) had proven KTpClPB encapsulation into 
polymeric nanoparticles although more than half of these molecules were lost during 
formulation. For all nanoparticle formulations, PLGA 502H, which has a high acid 
number (Table 4.1), was used. Acid number was directly correlated to the number of 
carboxylic acids present, thus higher acid number indicated increased binding potential to 
cationic hydrophilic small molecule drugs (Chapter 3, Fig 3.9).  
In this study, to properly compare between the two traditional emulsion 
formulations, initial doxHCl addition were maximized; although because the drug was 
loaded into different phases for the two emulsions using different methods, the maximal 
amounts in both cases were different.  
4.4.1.1 Comparison of traditional formulations  
 
 Previous data (Chapter 3, Fig 3.9) showed nanoparticles with smaller diameters 
had higher drug loading due to higher surface area/volume ratio and possibly higher 
charge density per particle. For this reason, KTpClPB-loaded W/O/W and O/W 
nanoparticles were each formulated at three different polymer concentrations (20, 30, or 
40 mg/mL) in ethyl acetate to try to reduce particle size while KTpClPB-free W/O/W 
nanoparticles were used as controls. 
4.4.1.1.1 SEM and particle sizing  
 
SEM images of nanoparticles showed spherical morphology for the different 
nanoparticles with average size between 100-200 nm (Fig. 4.6). For KTpClPB-loaded 
samples, reducing polymer concentration decreased nanoparticle size from 123.8 nm to 
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109.7 nm for O/W nanoparticles and from 115.8 nm to 95.8 nm for W/O/W particles (Fig. 
4.4C) with KTpClPB added. While not shown, W/O/W nanoparticles, without KTpClPB 
addition, were greater than 170 nm in diameter. This result proved KTpClPB 
incorporation could reduce particle size to a more desirable range of around 100 nm and 
reduced polymer concentration could also reduce particle size, although statistically, this 
might not be significant.  
4.4.1.1.2 Drug loading and encapsulation efficiency 
 
KTpClPB incorporation was important for drug loading as this increased from 
1.3% to 3.3% with addition of KTpClPB into W/O/W nanoparticles (Fig. 4.4A). 
Comparison between KTpClPB-loaded O/W and W/O/W nanoparticles showed O/W 
nanoparticles had higher drug loading across all polymer concentrations although the 
difference was only around 0.5% - 1% (Fig. 4.4B). Higher drug loading values for O/W 
nanoparticles were also deceiving because 5 mg of doxHCl was initially present during 
O/W nanoparticle formulation through extraction into the oil phase while only 2.5 mg 
doxHCl was dissolved in the inner aqueous phase of W/O/W nanoparticles during 
formulation (PLGA and KTpClPB amounts equal for both emulsions). This meant 
encapsulation efficiency, or amount of original drug added that was retained, was better 
for W/O/W nanoparticles, ranging from 62-71%, than O/W nanoparticles, which ranged 
from 37-53% (Fig. 4.4C). Because higher drug loading represented a potentially more 
efficacious dose while higher encapsulation efficiency could mean less wasted drug, it 
was important to know which property was more desirable in order to select a suitable 
formulation unless an improved drug loading strategy, which could maximize both 
factors, can be proposed.   
For both emulsion formulations with KTpClPB added, the highest loading was 
achieved at 20 mg/mL polymer concentration (3.3% for W/O/W and 3.8% for O/W 
nanoparticles), and both values were comparable to or better than previously published 
results for similar nanoparticles (Yoo, Oh et al. 1999; Yi, Kim et al. 2005; Chavanpatil, 
Khdair et al. 2007). Further increases in drug loading may be possible by increasing the 
theoretical drug loading (drug amount added/total material added, wt/wt) and this was the 
initial rationale behind reducing the polymer concentration while keeping initial drug 
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amount added constant. However, results from Fig. 4.4A and 4.4B suggested further 
reduction in polymer concentration might not achieve significant improvements. In 
addition, since the volume of the inner aqueous phase of W/O/W nanoparticles limited 
the amount of drug that could be initially added (due to solubility constraints) while 
doxHCl extraction into the oil phase of O/W nanoparticles was limited by KTpClPB 
solubility in the organic phase, the above drug loading values for these formulations 
appeared to be maximized and a new drug loading approach was required to dramatically 
improve drug loading. 
4.4.1.1.3 In vitro release 
 
 Desirable drug release profile for nanoparticles should be zero-order and lasting 
over several weeks. However, currently, unless drug molecules were chemically 
conjugated to individual polymers within a nanoparticle, it was difficult to achieve this. 
Typical in vitro drug release profiles for many polymeric nanoparticles showed an initial 
burst of over 40% within the first 3 hours of release (Soma, Dubernet et al. 2000; Wong, 
Bendayan et al. 2004; Missirlis, Kawamura et al. 2006) with limited release afterwards. 
For the present systems, in vitro drug release profiles were also biphasic with a relatively 
fast initial release within the first 3-6 hours followed by very slow release afterwards 
until a plateau starts to develop after 12-24 hours of release (Fig. 4.5). KTpClPB-loaded 
W/O/W nanoparticles showed the smallest burst release after 3 hours with less than 20% 
drug released, while KTpClPB-loaded O/W nanoparticles had the largest burst release 
after 3 hours with around 40% drug released. Despite a higher burst release within the 
first 3 hours, KTpClPB-loaded O/W nanoparticles demonstrated a more complete release 
after 2 days with 87% of total drug released while KTpClPB-loaded W/O/W 
nanoparticles only released 55% of total loaded drug. For W/O/W nanoparticles with no 
KTpClPB, there was a higher initial burst release, but also more complete release by 2 
days, relative to KTpClPB-loaded W/O/W nanoparticles.  
Based on the in vitro release profiles, drug release appeared to be diffusion-
controlled for all the formulations and KTpClPB did not offer obvious benefits for 
slowing down drug release. Other than that, it was hard to draw conclusions from this 
information given that KTpClPB-free W/O/W nanoparticles had less than half the drug 
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loading compared with KTpClPB-loaded W/O/W or O/W nanoparticles (Fig. 4.4) and 
due to random errors at different timepoints, it was also hard to conclude if any of the 
formulations demonstrated smaller burst release than the others. However, based on total 
drug release after two days, it was obvious O/W nanoparticles were more desirable for 
drug delivery than W/O/W nanoparticles.  
4.4.2 Reverse drug loading 
4.4.2.1 Description  
 
 Even though actual doxHCl loading into traditional W/O/W and O/W emulsion 
nanoparticles was relatively high according to previous results, an alternative strategy 
which might further increase drug loading and encapsulation efficiency was “reverse 
drug loading”, where blank nanoparticles were incubated in a concentrated drug solution 
to facilitate drug uptake (Fig. 4.7). In this case, since nanoparticles contained a lipophilic 
anion, KTpClPB, active drug uptake was possible via electrostatic interactions and 
potentially hydrophobic interaction (pi-pi stacking).  
 Blank nanoparticles in this study were formulated using a blend of PLGA (502H) 
and PEG-PLA (7:1, wt/wt) polymers with maximal KTpClPB addition. This system 
offered several advantages over existing systems in that 1) nanoparticle formulation was 
a simple O/W emulsion procedure with a simple washing process, 2) PEG polymer 
presence on nanoparticle surface created a hydrophilic shell to prevent protein adsorption 
and particle-particle aggregation, 3) KTpClPB promoted electrostatic interactions with 
cationic drug molecule such as doxHCl, 4) aromatic rings of KTpClPB provided 
additional hydrophobic interactions (pi-pi stacking) with aromatic rings on drug 
molecules such as doxHCl, and 5) higher acid number of PLGA (502H) led to more free 
carboxylic acids for additional charge-charge interactions with cationic drugs. 
 Several factors were further evaluated to optimize the reverse loading procedure 
before comparing this formulation with traditional emulsion formulations. 




 Drug absorption kinetics, or the rate at which drug molecules bind to 
nanoparticles, could be important because nanoparticle systems that take up drug quickly 
could offer time-saving advantages during manufacturing as well as potential applications 
for drug uptake in human body, where contact time between nanoparticles and dissolved 
drugs could be very short. For this study, a 12 hour incubation period was chosen and 
drug loading and encapsulation efficiency were determined after different incubation 
periods. Results showed there were no significant changes for either drug loading or 
encapsulation efficiency during this time (Fig. 4.8A). Drug loading varied from 3.8% to 
4.1% while encapsulation efficiency ranged from 61% to 67%. More interestingly, these 
values were reached instantly upon mixing (T = 0) and suggested KTpClPB-loaded 
PEGylated nanoparticles, unlike those KTpClPB-free nanoparticles that depended upon 
passive drug concentration gradient for loading, actively took up and retained drug 
molecules it came into contact with. Because incubation time did not appear to be 
significant with the present system, previous incubation time of 1 hour was kept for 
future studies.  
 Even though particle size did not change with incubation time, an unexpected 
result from this study was that zeta potential values became more positive with longer 
incubation time (Fig. 4.8B), changing from -30.8 mV to -18.3 mV after 12 hours, even 
though drug loading did not change significantly. A possible explanation for this 
phenomenon could be polymer rearrangement over time that either promoted KTpClPB 
intercalation into the core regions of nanoparticles or perhaps hydrophobic dox/KTpClPB 
ion pairs gradually changed the surface layer salt composition of nanoparticles over time. 
Another possible explanation could simply be instrument error. However, if these 
measurements were correct, then it suggested nanoparticles may aggregate after long 
incubation periods (not seen here as particle size remained the same) due to surface 
charge neutralization and suggested shorter incubation periods (less than 2-3 hours) were 
desirable. 
4.4.2.3 Optimization: polymer concentration 
 
 Studies with traditional W/O/W and O/W formulations, where doxHCl was 
encapsulated during particle formation, showed that reducing total polymer concentration 
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improved drug loading. With that in mind, the total polymer concentration of blank 
KTpClPB-loaded PEGylated nanoparticles were also decreased from 40 mg/mL in ethyl 
acetate to 20 mg/mL while the weight ratio between PLGA and PEG-PLA used was held 
constant. 
4.4.2.3.1 Characterization: SEM, sizing and zeta potential 
 
 SEM images of PEGylated nanoparticles (Fig. 4.11) with different polymer 
concentrations showed spherical particles with average size between 100-150 nm, 
matching readings from the particle sizing instrument (Table 4.2). An interesting 
observation here was that particle size decreased after reverse drug loading for all the 
different nanoparticles. This was likely due to formation of hydrophobic ion pairs 
between doxHCl and KTpClPB that created a more hydrophobic environment and drove 
more water out of nanoparticles, thus decreasing the hydrodynamic radius of 
nanoparticles recognized by the particle sizing instrument. Zeta potential of nanoparticles 
made with the smallest polymer concentration appeared to be the most negative (Table 
4.3), suggesting higher density of either PLGA polymer or KTpClPB or both per particle. 
For all three batches, there was initially a sharp increase in zeta potential (more positive) 
when increasing amounts of doxHCl was added into the incubation media, suggesting 
drug uptake and neutralization of surface charges. However, zeta potential values 
eventually reached a plateau and did not increase with addition of more doxHCl, 
suggesting any additional drug that was loaded into these nanoparticles localized into the 
inner core (or at least below the surface layer). 
4.4.2.3.2 Drug loading 
 
 The different PEGylated nanoparticles were incubated with different amounts of 
doxHCl up to 2 mg. Results showed drug loading increased with increasing amounts of 
doxHCl in the incubation media for all three batches of nanoparticles (Fig. 4.9). No more 
doxHCl was studied after 2 mg doxHCl because according to Fig. 4.9, there was no 
significant improvement in drug loading between addition of 1.5 mg and 2 mg doxHCl 
into the incubation media. The three batches of nanoparticles had the same trend as 
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traditional W/O/W and O/W emulsion formulations, as nanoparticles formulated at the 
smallest polymer concentration, 20 mg/mL, had the highest drug loading across the 
different drug amounts incubated. In fact, drug loading increased up to 7% when 2 mg of 
doxHCl was present in the incubation media for nanoparticles made at 20 mg/mL 
polymer concentration. However, one of the problems here was that even though drug 
loading increased dramatically, encapsulation efficiency decreased even more 
dramatically. Here again, a tradeoff between drug loading and encapsulation efficiency 
took place and it was important to see which one of the two factors were more important 
before deciding the initial amount of drug that should be added into the incubation media. 
4.4.2.3.3 In vitro release 
 
 Unlike drug loading results, doxHCl release profiles of all the PEGylated 
nanoparticles were similar (Fig. 4.10). Drug release was biphasic with an initial burst 
release of around 30% within the first three hours, followed by slower release afterwards 
until no more drug could be released after two days. Release was relatively complete with 
70% to 80% of total encapsulated drug released in the first 2 days for the different 
nanoparticles. Considering that drug loading in these particles were approximately 7%, 
6% and 6% for 20 mg/mL, 30 mg/mL and 40 mg/mL PEGylated nanoparticles, 
respectively, a significant amount of drug could be delivered using these systems to 
potentially enhance cancer cell cytotoxicity. 
 Based on similar release profiles for PEGylated nanoparticles and traditional 
W/O/W and O/W formulations with and without KTpClPB, this result again showed that 
KTpClPB incorporation was not beneficial for slowing down burst release even though 
electrostatic interactions between KTpClPB and doxHCl helped drug uptake and 
retention in nanoparticles. A likely hypothesis for this was that significant amounts of 
dissolved salts in the release media (phosphate-buffered saline) could compete with 
doxorubicin molecules for KTpClPB binding sites while the presence of sink release 
conditions, or virtually no drug in the release media, provided a reverse drug 




4.4.3 Comparison between traditional and reverse drug loading strategies 
 
 Despite excellent results obtained using both drug loading strategies, it was 
obvious that in terms of drug loading, reverse drug loading was a much superior method 
as 7% drug loading was almost twice that for drug loading values obtained using 
traditional emulsion formulations. This high drug loading, though, was reached by 
sacrificing encapsulation efficiency as this value decreased from 61-67% (3.8-4.1% drug 
loading) when 0.5 mg doxHCl was in the incubation media to ~33% (~7% drug loading) 
when 2 mg drug was present (all other conditions constant, data not shown). However, 
these values were still comparable to those for traditionally formulated emulsion 
nanoparticles, where encapsulation efficiency was 61.9% (3.2% drug loading) for 
KTpClPB-loaded W/O/W nanoparticles and 37.4% (3.8% drug loading) for KTpClPB-
loaded O/W nanoparticles. The above data showed that at similar drug loading levels, 
encapsulation efficiency for reverse loading nanoparticles was comparable to or better 
than traditional drug loaded formulations. In addition, with similar drug release profiles 
and similar release rates, reverse loaded nanoparticles, with much higher drug loading, 
would be expected to release more absolute amounts of drug at different timepoints and 
promote efficacy. 
 With the above information in mind, it was clear that reverse drug loading was a 
more powerful drug loading and drug delivery tool compared to more commonly used 
strategies and it would also be interesting to see how well reverse loaded nanoparticles 
work as delivery vehicles. 
4.5 Conclusion 
 
 Results showed that ion pairing strategy, using KTpClPB, could be used to 
improve drug loading and encapsulation efficiency of doxorubicin hydrochloride into 
either traditionally formulated nanoparticles or reverse loaded nanoparticles. 
Comparatively, traditional formulations, where drug was encapsulated during 
nanoparticle formation, was a more cumbersome process relative to the more flexible 
reverse loading procedure and produced larger sized nanoparticles. With KTpClPB 
incorporation, reverse drug loading, or incubation of doxHCl with preformulated blank 
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nanoparticles, produced the best results and obtained twice the drug loading after 
optimization, at 7%, compared with traditional formulation where doxHCl was 
encapsulated during nanoparticle formation. Unlike previous reports suggesting ion 
complexation strategy could obtain zero-order drug release, here, using KTpClPB as ion 
pairing agent, doxHCl release profile was not improved and burst release did not show 
significant reduction. These results showed reverse drug loading strategy was a more 
powerful tool for making drug delivery vehicles and these systems could potentially be 
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Table 4. 2. Size and zeta potential of PEGylated nanoparticles before and after reverse 
drug loading (all 3 batches of nanoparticles had similar sizes before and after drug 
loading regardless of initial drug added) as a function of polymer concentration used 
during nanoparticle preparation 
Representative particle size (nm) 
Polymer 
Concentration 
Before drug loading After drug loading 
20 mg/ml 128.8 99.1 
30 mg/ml 138.2 113.2 





































Table 4. 3. Zeta potential of PEGylated nanoparticles before and after reverse drug 
loading as a function of doxHCl loading concentration 
Zeta potential of different 
nanoparticle formulations (mV) DoxHCl in incubation 
media (mg) 
20 mg/ml 30 mg/ml 40 mg/ml 
0 (blank) -35.7 -38.3 -41.9 
0.5 -20.0 -30.9 -31.4 
1 -30.2 -28.1 -30.2 
1.5 -26.9 -25.6 -30.9 






































Figure 4. 1. Structure of doxorubicin hydrochloride (doxHCl), right, and potassium 



















































5,000 25,000 19408.54 22689.8 
1
 Calculated based on wt ratios of PEG and l-lactide added during PEG-PLA synthesis 
2
 Calculated based on area ratios of peaks A and B 
3
 Caclulated based on area ratios of peaks A and C 
 
 
Figure 4. 2. (A) 
1
H-NMR spectrum of methoxyPEG-PLA copolymer in 
deuterochloroform and (B) associated table with theoretical and calculated molecular 





































4 mL 3% PVA 
probe sonicate for 20 sec to 
form W/O/W emulsion 
stir 4-5 hrs 
end product: W/O/W or O/W nanoparticles 
Probe sonicate 20 sec to form W/O 
(primary) emulsion or only use 
ethyl acetate for O/W emulsion 
2 mL ethyl acetate with polymer 
and with(out) borate 
0.25 mL water with 2.5 mg doxHCl 
wash with stir cell 





























20 mg/ml 61.9 37.4 95.8 109.7 
30 mg/ml 69.5 46.0 107.0 112.3 
40 mg/ml 70.9 53.0 115.8 123.8 
*
 Nanoparticle sample denoted by polymer concentration used for nanoparticle 
preparation 
 
Figure 4. 4. Drug loading comparison between W/O/W nanoparticles with and without 
KTpClPB encapsulation (A) and comparison between KTpClpB loaded W/O/W and O/W 
























































































Figure 4. 5. In vitro doxHCl release curve for drug-loaded W/O/W nanoparticles (with 































































Figure 4. 6. SEM images of drug-loaded W/O/W nanoparticles (A and B), drug and 
KTpClPB-loaded W/O/W nanoparticles (C and D) and drug and KTpClPB-loaded O/W 


















































































Incubation time (hr) Zeta potential (mV) Particle size (nm) 
0 -30.8 125.1 
0.5 -30.1 122.5 
1 -29.7 124.2 
2 -29.9 124.7 
3 -26.7 123.3 
12 -18.3 123.3 
 
 
Figure 4. 8. Drug loading, encapsulation efficiency (A) and associated particle zeta 




























































































Figure 4. 9. Reverse doxHCl loading into PEGylated nanoparticles formulated at 20, 30, 
or 40 mg/ml total polymer concentration at different doxHCl to nanoparticle weight ratio 
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Figure 4. 10. In vitro doxHCl release from PEGylated nanoparticles formulated at 
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Figure 4. 11. SEM images of drug-loaded PEGylated nanoparticles formulated at 20 
mg/ml (A and B), 30 mg/ml (C and D), and 40 mg/ml (E and F) total polymer 
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5.1 Ion Pairing 
 
 Ion pairing has been an important strategy widely applied in the last several 
decades. Starting as a strategy where an excipient was used to preserve protein integrity 
and stability, it has been adapted to small molecule drugs, such as anticancer drugs (e.g. 
cisplatin), to change their hydrophilic-lipophilic balance (HLB) and obtain desirable 
solubility properties. More recently, although not specifically mentioned, this strategy has 
contributed to improved drug encapsulation into nanoparticles. An area that has yet to be 
investigated, though, was whether small molecule lipophilic anions could be coupled to 
small molecule hydrophilic cationic drugs to form new complexes with increased 
hydrophobicity and achieve their encapsulation into hydrophobic cores of polymeric 
nanoparticles. This strategy could be advantageous for improving drug loading and 
encapsulation efficiency, slowing down drug release, providing treatment for drug 
overdoses, and domestic applications such as water treatment. 
5.1.1 Alkyl sulfates 
 
 Alkyl sulfates, such as sodium dodecyl sulfate (SDS), represent a class of 
potentially useful lipophilic anions; they are amphiphilic molecules with hydrophobic 
carbon chains and hydrophilic, anionic sulfate groups (Fig. 2.1). Ion complexation of 
these compounds with amine groups on doxorubicin hydrochloride (doxHCl) could form 
hydrophobic ion pairs with hydrophobicity that increases with increasing carbon chain 
length of alkyl sulfates. In the first part of this study, doxorubicin complexes were 
successfully formed in water using sulfates such as sodium octyl sulfate (SOS), sodium 
dodecyl sulfate (SDS), sodium tetradecyl sulfate (STS), and sodium octadecyl sulfate 
(SODS), indicating presence of new classes of doxorubicin drug that maintained the 
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integrity of doxorubicin hydrochloride but changed its solubility. As expected, aqueous 
solubility decreased significantly with increasing alkyl chain length (from 17.24 mM for 
doxHCl to 0.011 mM for doxSODS) and increasing methylene chloride/PBS partition 
coefficient (from 0.33 for doxSOS to 2.49 for doxSODS), while similar EC50 values for 
doxHCl and various doxorubicin complexes showed that cell cytotoxicity was primarily 
caused by doxorubicin itself, with the complex dissociating before doxorubicin can exert 
its effect. Even though these novel drug complexes were hydrophobic with low aqueous 
solubility, beneficial for slowing drug release in aqueous media, a critical problem with 
these complexes was that they did not dissolve at high concentrations in organic solvents 
commonly used for nanoparticle formulation, such as methylene chloride, chloroform, 
and ethyl acetate; nor do they dissolve well in solvents miscible with organic solvents 
such as methanol, acetone, and acetonitrile. Because of the solubility issue, emulsion 
formulations specially tailored for the complexes, solid-in-oil-in-water (S/O/W) and 
water-in-oil-in-water (W/O/W), achieved minimal drug loading. 
5.1.2 Alkyl borates 
 
 Although alkyl sulfate studies failed in its final goal of significantly improving 
drug loading in nanoparticles, this was significant because it was the first time such small 
molecules had been ion paired with a drug like doxorubicin hydrochloride. More 
importantly, this study showed ion pairing for drugs like doxorubicin could form new 
entities and this overall strategy should be pursued while the ion pairing agent, alkyl 
sulfate, should be exchanged for lipophilic anions with proven solubility in organic 
solvent commonly used for nanoparticle formulation. After rigorous search, borate-based 
lipophilic anions were selected as model lipophilic anions for further studies (Fig. 3.2).  
Borate-based anions have negatively charged borates for ion pairing as well as 
four aromatic rings connected to the central boron for potential hydrophobic interactions 
(pi-pi stacking) with drug molecules such as doxorubicin. Solubility studies for different 
borates in this study showed poor solubility in methylene chloride and chloroform, but 
solubility in ethyl acetate reached 2.5 mg/mL, which was significant because ethyl 
acetate was commonly used to formulate emulsion-based nanoparticles. Extraction in 
ethyl acetate showed dissolved borate molecules could take up doxorubicin and there was 
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an approximately 1:1 molar extraction of doxHCl by NaTPB, KTpClPB, and 
KTBTFMPB, proving that 1) hydrophilic doxHCl could be easily and quickly extracted 
into a hydrophobic phase at high concentrations, 2) charge-charge interactions dominated, 
and 3) borate compounds, if incorporated into nanoparticles, could extract doxHCl in 
case of drug overdose to reduce toxicity. Because of leaching concerns with NaTPB and 
price of KTBTFMPB, KTpClPB was ultimately chosen for nanoparticle incorporation.   
5.2 Nanoparticle formulation 
5.2.1 Blank nanoparticle formation 
 
 Knowing KTpClPB could extract the model hydrophilic drug, doxHCl, from the 
aqueous to ethyl acetate phase and that the KTpClPB/doxorubicin complex had relatively 
high solubility in ethyl acetate, it was important to determine two things. First, whether 
KTpClPB-loaded polymeric nanoparticles could be formulation; second, if these 
nanoparticles, when suspended in a doxHCl solution, could take up drug to reach high 
loading (reverse drug loading) and factors that influence this process; and third, how 
reverse drug loading compare to traditional drug loading procedures such as water-in-oil-
in-water (W/O/W) and oil-in-water (O/W) where drug is loaded during nanoparticle 
formation.  
 Formulation of KTpClPB-loaded polymeric nanoparticles via O/W procedure and 
reverse loading of doxHCl were very simple and scaling up should present minimal 
difficulty although this was not studied. KTpClPB incorporation into nanoparticles was 
proven through extraction and with theoretically maximal KTpClPB loading, less than 
half of the KTpClPB present was actually encapsulated into nanoparticles. This 
demonstrated an upper limit on the weight percent of KTpClPB encapsulation into 
nanoparticles and that improving drug loading had to rely on more than simply KTpClPB 
co-incorporation into nanoparticles.  




Some important variables tested for improving drug uptake were selected based 
on the components of the reverse loading procedure and results showed that 1) 
maximizing the acid number of polymers introduced more free acid groups (via 
carboxylic acids) available for ion complexing with doxHCl and higher loading and 
encapsulation efficiency , 2) maximizing KTpClPB incorporation continuously increased 
doxHCl loading, presumably due to charge interactions although hydrophobic 
interactions may also play a small role, 3) increasing drug:nanoparticles (wt/wt) ratio 
increased the concentration gradient to drive drug into the nanoparticles, 4) formulating 
PEGylated instead of regular nanoparticles reduced nanoparticle aggregation caused by 
surface charge neutralization, 5) making smaller nanoparticles by decreasing polymer 
concentration to boost the surface area/volume ratio and potentially increase KTpClPB 
percent loading, and 6) in an observation previously reported by Kang et al., increasing 
incubation temperature from room temperature to 37
o 
C increases drug loading and 
encapsulation efficiency through increasing polymer rearrangement within nanoparticles. 
Altogether, the improvements above increased loading for two model drugs, 
doxHCl and vinblastine sulfate (VS), in KTpClPB-loaded polymeric nanoparticles to as 
high as 7% and 9%, respectively, while nanoparticles averaged between 100-160 nm in 
diameter with spherical morphology. This demonstrated broad applicability of this 
reverse loading procedure and specially formulated nanoparticles toward this entire class 
of drugs as well as the effectiveness of ion complexation strategy using KTpClPB. An 
area requiring further improvement was the poor drug release profile, which showed up 
to 30% total drug release within the first three hours, 70-80% by 24 hours and essentially 
no release afterwards. This result was different from results shown by Chavanpatil et al, 
where AOT-based nanoparticles provided sustained release of water-soluble drugs. 
However, in their study, AOT, a lipophilic anion, was chemically conjugated to 
nanoparticles as opposed to simple physical incorporation of KTpClPB into polymeric 
nanoparticles in this study. More importantly, the result showed that adsorption loading, 
although simple and effective and widely used for protein loading, could result in particle 
aggregation if charges on nanoparticle surfaces are neutralized in the absence of surface 
hydrophilic moieties such as PEG. However, in certain cases where drug removal in non-
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physiological settings is required, this aggregation/sedimentation could prove to be a 
useful mechanism. 
5.3 Traditional versus incubation drug loading  
 
 Comparison between traditional drug entrapment (O/W and W/O/W), where drug 
loaded into nanoparticles during its formation, was compared with the optimized reverse 
drug loading procedure, or drug loading after nanoparticle formation. Traditional 
entrapment strategies (O/W and W/O/W) showed dramatically improved drug loading 
and encapsulation efficiency with KTpClPB incorporation, as doxHCl loading increased 
from 1.3% for W/O/W nanoparticles with no KTpClPB to more than 3.3% with 
KTpClPB added; and encapsulation efficiency increased from a high of 22% for W/O/W 
nanoparticles with no KTpClPB, to more than 62% for O/W and more than 38% for 
W/O/W nanoparticles with KTpClPB addition. As promising as these improvements 
were, they dimmed in contrast to the ~7% drug loading obtained through reverse drug 
loading although encapsulation efficiency was sacrificed for high drug loading for 
reverse loading method. Furthermore, drug release profiles for traditional drug loading 
and reverse loading nanoparticles showed no significant difference. With these 
comparisons in mind, reverse drug loading was not only a simpler, but also a more 
effective strategy for optimizing drug loading; this study was also important as it 
demonstrated that KTpClPB presence in nanoparticles enhanced drug loading, regardless 
of when drugs were actually added to nanoparticles.  
5.4 Plasma drug uptake 
 
 As mentioned before, one of the new areas of research was use of nanoparticulate 
materials to take up drug and promote detoxification. Despite demonstrating 
detoxification potential in vitro (in deionized water), almost none of the studies showed 
how well their systems might work in vivo, where numerous substances present in blood, 
such as competing salts and plasma proteins, may interfere with drug uptake. Since 
KTpClPB-loaded polymeric nanoparticles demonstrated excellent drug uptake properties, 
it was interesting to see if they could do the same when in plasma. Because a large-scale 
 169 
 
and expensive in vivo study is unwarranted if these nanoparticles cannot take up 
significant amounts of drug under physiological conditions, doxHCl uptake in plasma 
was examined. Results of the plasma drug uptake study was very interesting as low 
doxHCl concentrations (those at or near normal therapeutic concentrations) showed 
minimal drug uptake, while at three or four times the normal therapeutic concentration, 
drug uptake efficiency and nanoparticle drug loading increased dramatically. This type of 
result, which had not been shown before, supported the applicability of this nanoparticle 
system as not only a high loading drug carrier, but a potentially useful drug detoxification 
system which does not reduce drug efficacy when a normal dose is administered but can 
reduce toxicity when toxic levels are reached. 
5.5 Use of Borate-Based Compounds for Ion Pairing 
 
  Despite significant improvements in doxorubicin and vinblastine loading into the 
specially formulated ion-complexing nanoparticles in this study, one of the main 
concerns in this study was the use of potassium tetrakis(4-chlorophenyl)borate (KTpClPB) 
as the ion pairing agent.  
 By itself, boron is actually present in the human diet and up to 2 mg of boron may 
be ingested daily (Sahelian). However, KTpClPB is a compound which is known to be 
harmful when ingested . Because there have been no studies of KTpClPB toxicity in 
animals or humans, the safety of using KTpClPB-loaded nanoparticles, even at very 
small amounts such as those in this study, still presents an obstacle for therapeutic use.  
 With the above precaution in mind, one of the alleviating factors could be that 
they are incorporated into nanoparticles and do not appear to leach. Nanoparticles in the 
human body may be cleared by various organs, especially those of the reticuloendothelial 
system (liver and spleen) and kidneys. This means that within a few days of nanoparticle 
administration, those that do not concentrate at tumor sites should be removed by body 





 Results from reverse loading experiments using KTpClPB-loaded nanoparticles 
presented some interesting possibilities. In addition to their potential as detoxifiers, these 
nanoparticles, with rapid uptake of cationic small molecule drugs or peptides/proteins, 
may be applied to extraction of other cationic molecules. In addition, reverse loading, in 
combination with ion complexation using KTpClPB, may be applied to carriers such as 
microspheres to create effective drug depots. With a larger diameter and potential for 
increased KTpClPB loading, drug loading in microspheres could be significantly 
improved while the smaller surface area-to-volume ratio of microspheres may promote 
sustained drug release over many months. Another interesting application for KTpClPB-
loaded nanoparticles may be water purification where cationic metals such as calcium 
and magnesium are removed to reduced water hardness. Here, aggregation and 
sedimentation of drug loaded, non-PEGylated nanoparticles may actually be desirable as 
a mechanism for its removal from purified water. 
 
 
 
 
 
 
